PROGRAMME - Tox€¦ · Pharmacology (DGP/SPS/DZHK – Preclinical Drug Development) 40 EUR...

3rd GERMAN PHARM-TOX SUMMIT

© Götti ngen Tourismus e. V.

26 February–1 March GÖTTINGEN | 2018

84. Jahrestagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie (DGPT) und 20. Jahrestagung des Verbundes Klinische Pharmakologie (VKliPha) in Zusammenarbeit mit der AGAH

PROGRAMME

4th GERMAN PHARM-TOX SUMMIT

© Stadtblick Stutt gart l Fotolia.com

SAVE THE DATE

85. Jahrestagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie (DGPT)

und 21. Jahrestagung des Verbundes Klinische Pharmakologie (VKliPha) in Zusammenarbeit mit der AGAH

25–28 FEBRUARY STUTTGART l 2019

SCANGPTS-KONGRESS.DE

3

Table of conTenTs

Organisation and imprint ........................................................................................................... 4

Welcome note ............................................................................................................................ 5

General information Venue ................................................................................................................ 6 Certification ...................................................................................................... 6 Registration fees ............................................................................................... 7 Catering, Opening hours .................................................................................. 8 Publication of abstracts, Awards ...................................................................... 9

General hints for authors and oral presenters ......................................................................... 10General hints for poster presentations ..................................................................................... 12

Social programme ...................................................................................................................... 14Media cooperation and company descriptions ......................................................................... 15Sponsors and exhibitors ............................................................................................................ 16Floor plan of venue and exhibition area ................................................................................... 17

Programme overview Monday, 26 February ....................................................................................... 18 Tuesday, 27 February ....................................................................................... 19 Wednesday, 28 February ................................................................................. 20 Thursday, 1 March ........................................................................................... 21

Special meetings ........................................................................................................................ 22

Scientific programme Monday, 26 February ....................................................................................... 24 Tuesday, 27 February ....................................................................................... 27 Wednesday, 28 February ................................................................................. 35 Thursday, 1 March ........................................................................................... 48

AGAH Workshop • Wednesday, 28 February ............................................................................ 46

Poster sessions Poster session I • Tuesday, 27 February .......................................................... 56 Poster session II • Wednesday, 28 February ................................................... 73

Index of presenting authors and chairs ..................................................................................... 89

4th GERMAN PHARM-TOX SUMMIT

© Stadtblick Stutt gart l Fotolia.com

SAVE THE DATE

85. Jahrestagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie (DGPT)

und 21. Jahrestagung des Verbundes Klinische Pharmakologie (VKliPha) in Zusammenarbeit mit der AGAH

25–28 FEBRUARY STUTTGART l 2019

SCANGPTS-KONGRESS.DE

4

ORGANISATION AND IMPRINT

Hosting societiesDeutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie e. V. (DGPT) www.dgpt-online.de

Verbund Klinische Pharmakologie in Deutschland e. V. (VKliPha)www.vklipha.de

Arbeitsgemeinschaft für Angewandte Humanpharmakologie e. V. (AGAH)www.agah.eu

Conference chairsProf. Dr. Jürgen BrockmöllerInstitute of Clinical PharmacologyUniversity Medical Center Göttingen

Prof. Dr. Wolfram-Hubertus ZimmermannInstitute of Pharmacology and ToxicologyUniversity Medical Center Göttingen

Scientific committeeProf. Dr. Holger Barth (Ulm)PD Dr. Kurt Bestehorn (Ebenhausen)Prof. Dr. Jürgen Brockmöller (Göttingen)Dr. Andrea Kliewer (Jena)Dr. Barbara Schug (Oberursel)Prof. Dr. Matthias Schwab (Stuttgart, Tübingen)Prof. Dr. Thomas Wieland (Mannheim)Prof. Dr. Wolfram-Hubertus Zimmermann (Göttingen)

Professional congress organiserConventus Congressmanagement & Marketing GmbHTina Markert/Cyntia RammelPhone +49 3641 31 16-367/[email protected] I www.conventus.de

Design/layoutLayout krea.tif-studio UG (limited liability)Print Silber Druck OhgCirculation 1,000Editorial deadline 12 February 2018

5

WelcoMe noTe

Dear colleagues and friends,

It is our great honour to host the 3rd German Pharm-Tox Summit in Göttingen from 26 February–1 March 2018. As in the past years, the conference will be held by the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) together with the Association of Clinical Pharmacology (VKliPha) and the Association for Applied Human Pharmacology (AGAH). With the excellent support by Conventus, we will do everything to make the German Pharm-Tox Summit 2018 a memorable event. The city of Göttingen, mentioned for the first time in 953 as Gutingi, has been a city of science for more than 200 years.

Famous scientists like Carl Friedrich Gauß carried out their research in Göttingen. Altogether 46 Nobel laureates, including Robert Koch in 1905 and more recently Stefan Hell in 2014, framed collectively the „Nobelpreiswunder“ of Göttingen. The Georg-August University with its 30,000 students, five Max-Planck-Institutes and other renowned research institutions with a large com-munity of international scientists create a truly scholarly atmosphere in Göttingen.

Göttingen is located in the beautiful landscape environment of the German Fairy Tale Route. Its well-preserved historic old city is remarkable for its many half-timbered houses and other build-ings, quite a few of them being older than 500 years.

All of you who have already been to Göttingen may be happy to come again, and all of you who have not been here yet will surely keep it in best memories.

We wish you a successful conference and a great time here in our city of science.

Welcome to Göttingen!

Jürgen Brockmöller Wolfram-Hubertus Zimmermann Prof. Dr. Matthias SchwabConference chair 2018 Conference chair 2018 President DGPT

Prof. Dr. Thomas Wieland Prof. Dr. Holger Barth PD Dr. Kurt BestehornPresident DGP President GT Speaker VKliPha

Dr. Barbara Schug President AGAH

GENERAL INFORMATION

6

Venue Georg-August-University Göttingen Central lecture building (ZHG) Platz der Göttinger Sieben 5 37073 Göttingen (DE)

@

Conference website www.gpts-kongress.de

Online programmeFor current detailed information regarding the scientific programme, please have a look at programm.conventus.de/gpts2018. Compose your individual programme and review it at any time on your way.

CertificationAn application was handed in to the Medical Association of Lower Saxony (Niedersachsen) as follows:Tuesday, 27 February Category B 6 PointsWednesday, 28 February Category B 6 PointsThursday, 1 March Category B 6 Points

Certificate of attendancePlease scan your EFN barcode daily at the EFN certification counter next to the check-in. The certificate of attendance will be printed automatically. The points will be transferred to the Medical Association of Lower Saxony (Niedersachsen) electronically.

a general certificate of attendance can be printed with the barcode on your name badge at the certification counter. Your name badge also provides access to the scientific sessions and to the industrial exhibition. Therefore, please wear your name badge during the whole conference.

GENERAL INFORMATION

7

Registration fees

Late registration Registration on-site until starting from 22 February 26 FebruaryMember(DGPT, VKliPha, AGAH) 170 EUR 210 EURNon-member 250 EUR 290 EURStudent 120 EUR 140 EURRetiree 120 EUR 140 EUR

Day tickets (27 Feb–1 Mar)Member (DGPT, VKliPha, AGAH) 120 EUR Non-member 140 EUR

Advanced Courses (26 Feb)Advanced CoursePharmacology (DGP/SPS/DZHK – Preclinical Drug Development) 40 EURAdvanced Course Clinical Pharmacology 40 EURAdvanced Course Toxicology 40 EUR

AGAH Workshop (28 Feb) 75 eUR

Social programme*Get together (27 Feb) free of chargeSocial evening (28 Feb) 60 EUR

* Booking is only possible with a registration for the German Pharm-Tox Summit.

GTC

General terms and conditions Please find our general terms and conditions at www.gpts-kongress.de.

Payment and confirmation of paymentIn case of online registration, an invoice or confirmation of registration will be sent to you via postal or electronic mail within 14 days. This invoice is a valid invoice which may be submitted to the local tax and revenue office. All fees are due upon receipt of invoice/registration confirmation. Payment transfers must include participant´s name and invoice number. Payment is also accepted by credit card (Master-/Eurocard, American Express, VISA). In case you have transferred the registration fee shortly before the start of the congress, (up to 10 days prior to congress opening) we would like to ask you to present your transfer remittance slip on-site.

GENERAL INFORMATION

8

Self check-inThe self check-in is located next to the check-in. In case of full and timely payment by 19 February, you will receive your personal QR code via e-mail for a fast and easy self check-in. Please bring your QR code either printed or on your smartphone to the conference.

EvaluationPlease take a few moments to fill out the evaluation form to help us to refine and improve the upcoming conferences. There will be an online evaluation possible after the conference at www.gpts-kongress.de/evaluation.

Catering on Monday (Advanced courses)The bistro will be open the entire day on a self-payment basis. Furthermore, some refreshments are offered free of charge.

Catering from Tuesday until ThursdayThe bistro, which is located close to the plenary hall (HS 011), offers refreshments at own expense. It is open during the conference hours. In the coffee breaks we offer coffee and tea free of charge in the industrial exhibition. There will be no catering during lunchtime (except during the Get together on Tuesday, 12:45–13:30). On Wednesday there is a industrial symposium with lunch bags sponsored by Agilent Technologies.

Industrial exhibitionA specialised industrial exhibition accompanies the conference. The exhibitors are looking forward to welcoming you and to present their comprehensive range of innovative prod-ucts. For a detailed layout of the exhibition plan see page 17. Please note that sponsors and exhibitors take essential credits for making this conference possible.

CloakroomThere is the possibility to hand in your coat at the cloakroom for 1 EUR/piece. The coat and luggage room is located in the foyer of the 1st floor next to the media check-in.

Service for impaired peopleAll rooms are accessible by wheelchair.

Opening hours Monday Tuesday Wednesday ThursdayCheck-in 09:30–17:00 08:00–18:00 08:00–17:30 08:00–13:30Media check-in 09:30–17:00 08:15–16:15 08:15–17:15 08:15–13:30Industrial exhibition 10:30–16:15 10:30–17:15 10:30–13:30Cloakroom 09:30–18:15 08:15–19:15 08:15–19:15 08:15–15:30

GENERAL INFORMATION

9

Internet corner and WIFI accessFree WIFI is available throughout the whole building.You will receive the login details on-site.

Conference languageThe conference language is English. Several presentations and sessions will be held in German. They will be marked in the detailed programme. Short presentations have to be presented in English only.

Publication of abstractsAll abstracts will be published online in the “Naunyn-Schmiedeberg‘s Archives ofPharmacology” of the publisher Springer Basel (Basel/CH) and are available online on the conference website www.gpts-kongress.de from 19 February until 15 March 2018.

Scientific supportersThe German Pharm-Tox Summit is funded by:

Awards

The following awards will be granted during the German Pharm-Tox Summit at the award ceremony on 28 February, 18:45–19:15, HS 009:

• Young Scientist Toxicology Merck Award, sponsored by Merck KGaA, Darmstadt• Buchheim-Preis

In addition, awards are granted for the best oral and poster presentations. A selected jury will review the presentations during the conference. The prizes will be awarded during the closing ceremony on Thursday, 15:00, in the lecture hall HS 009. We would like to invite all abstract authors to participate. The following awards will be granted:

Toxicology• GT-Toxicology Preis, sponsored by the Society of Toxicology and the journal “Toxicology“• GT-Poster award• GT-Award for the best oral presentation• GT-Toxins award for the best poster in the section “Biogene Toxine” sponsored by the Journal “Toxins” (Basel)

Pharmacology• Poster awards

Tuesday, 27 February at the social evening Forum Young Scientist• FJW Science Slam Award sponsored by Prof. Dr. Holger Barth and Prof. Dr. Dr. Siegfried G. Schäfe

10

GENERAL HINTS FOR AUTHORS AND PRESENTERS

Submission of a presentation/technical informationPlease prepare your presentation in 4:3 aspect ratio.Please clarify possible conflicts of interest at the beginning of your talk.A presentation notebook with a PDF reader and MS Office PowerPoint 2016 will be provided. The use of personal notebooks is possible upon agreement. However, it may interrupt the flow of the programme in the lecture hall. Please provide an adapter for VGA if necessary. To guarantee a smooth running programme, please upload your presentation in time – at least 2 hours before your presentation is due to start. Should you wish to use non-digital equipment, please contact us at [email protected].

Presentation upload – Media check-inThe speakers ready room for uploading your presentation is located in the foyer of the 1st floor.For submission, please use a USB flash drive, CD or DVD disc that is not protected by any software. Professional staff and equipment will be available for you to arrange and preview your presentation.

Time allocationPlease prepare your presentation for the allotted amount of time. Chairs and moderators may interrupt should you overrun your time limit. Speakers of short presentations have a time frame of 15 minutes (including 3 minutes of discus-sion time).

GENERAL INFORMATION

11

Die Arzneimitteltherapie informiert Sie über etablierte und neue Arzneistoff e und deren therapeutischen Stellenwert. Damit Sie aus dem Fundus an Arzneimitteln eine gut begründete Auswahl für Ihre Therapieentscheidung treff en können.

Überzeugen Sie sich selbst und testen Sie die Arzneimitteltherapie 3 Monate gratis im Probeabonnement.

Infos und Bestellung:

www.arzneimitteltherapie.de

Telefon: 0711 / 2582-353

ARZNEIMITTEL

ABO_AMT_1-2 hoch_2018_2indd.indd 1 24.01.18 10:03

12

GENERAL HINTS FOR POSTER PRESENTERS

Your poster must be prepared in English, DIN A0 (84.1 cm wide x 118.9 cm high) and in vertical format. Pins will be provided on your poster board. Please do not use any other type of pins than those provided. All poster boards will be labelled with a poster number. You can find your poster number in the programme on page 56–88.Please note that the poster session will be split into two parts. However, posters will be shown during the whole conference.

Posters should be mounted by Monday or Tuesday morning and be removed, at the latest, by Wednesday, 28 February, 19:00. Posters that have not been removed by this time will be diposed.

The presenting authors must be present during the dedicated poster session:Poster Session I – Tuesday, 13:30–14:30Poster Session II – Wednesday, 13:00–14:00

Poster Session I ID page

Foyer ground floorPharmacology – Endocrine pharmacology P01–P08 56Pharmacology – G-protein coupled receptors I P09–P16 57Pharmacology – Cardiovascular pharmacology & treatment I P17–P24 58Pharmacology – Cardiovascular pharmacology & treatment II P25–P32, P153 59Pharmacology – Central nervous system pharmacology P33–P40 60Pharmacology – GTP-binding proteins & cyclic nucleotides I P41–P48 61Pharmacology – Immunopharmacology P49–P56 62Pharmacology – Membrane transporters I P57–P63 63Pharmacology – Cancer pharmacology & treatment I P64–P69 63Clinical Pharmacology – In vitro systems and disease models P70–P81 64Clinical Pharmacology – Research in clinical pharmacology P82–P87 65

Foyer 1st floorToxicology – Biotransformation and toxicokinetics P88–P92 66Toxicology – Organ toxicology P93–P105 67Toxicology – Methods in toxicology P106–P111 68Toxicology – Genotoxicity/carcinogenesis P112–P119 69Toxicology – Toxicology of nanomaterials P120–P124 70Toxicology – Toxins P125–P137a 71General – Education P136–P141 72

As a full-service PCO, we provide you with intelligent and innovative solutions in an advisory and implementing manner.

www.conventus.de

© v

icto

r zas

tol's

kiy

/ Fot

olia

13

GENERAL HINTS FOR POSTER PRESENTERS

Poster Session II ID page

Foyer 1st floorPharmacology – Cancer pharmacology & treatment II P142–P148 73Pharmacology – Cardiovascular pharmacology & treatment III P149–P156 74Pharmacology – Cardiovascular pharmacology & treatment IV P157–P165 75Pharmacology – Cardiovascular pharmacology & treatment V P166–P174 76Pharmacology – Enzymes P175–P182 77Pharmacology – G-protein coupled receptors II P183–P190 78Pharmacology – GTP-binding proteins & cyclic nucleotides II P191–P198 79Pharmacology – Ion channels P199–P205 80Pharmacology – Membrane transporters II P206–P212 81Clinical Pharmacology – Pharmacogenomics & personalised therapy P213–P219 81Clinical Pharmacology – Pharmacokinetics and PK-PD modelling P220–P227 82Toxicology – In silico methods in toxicology P228–P231 83Toxicology – In vitro methods in toxicology P233–P258 84Toxicology – Biomonitoring/biomarkers in toxicology P259–P266 87Toxicology – Food toxicology P267–P273 88

As a full-service PCO, we provide you with intelligent and innovative solutions in an advisory and implementing manner.

www.conventus.de

© v

icto

r zas

tol's

kiy

/ Fot

olia

14

SOCIAL PROGRAMME

Tuesday, 27 FebruaryGet together Come together for drinks and snacks at the fi rst conference day and enjoy your lunch break together in the industrial exhibiti on. Allow yourself interesti ng conversati ons with colleagues, old friends, exhibitors and make new acquaintances.

Time 12:45–13:30Venue Industrial exhibiti onPrice Included in conference fee

Social evening – Forum Junge Wissenschaft The Forum Young Scienti sts invites you to the fi rst FJW Science Slam DGPT 2018.The Science Slam taking place on the 27 February at 19:30 in the Wirtshaus: „Zur alten Brauerei“, Düstere Straße 20a in Göt-ti ngen. The aim is to present research work comprehensibly, vividly, and entertaining. The audience will decide by applause, who will be awarded with the FJW Science Slam Award 2018. The award is sponsored by Prof. Dr. Holger Barth and Prof. Dr. Dr. Siegfried G. Schäfer. Don’t miss the chance where young scienti sts present their topics in the community.

Time 19:30Locati on Zur alten Brauerei Düstere Straße 20a 37073 Götti ngenDistance to venue 1.4 kmprice 15 eUR

Wednesday, 28 FebruarySocial evening of the conferenceCome together for a fantasti c evening! The social evening is in the “Bullerjahn” directly in the center of Götti ngen. Enjoy delicious German food during interesti ng conversati ons.

Time 19:45–23:30Locati on BULLERJAHN Markt 9 37073 Götti ngenDistance from venue 1.8 kmprice 60 eUR

© Rawpixel.com l Fotolia.com

© Bullerjahn

© smolaw11 l Fotolia.com

15

MEDIA COOPERATION AND COMPANY DESCRIPTIONS

Media cooperationSpringer Basel AG (Basel/CH)Naunyn-Schmiedeberg’s Archives of Pharmacology

Springer Basel AG (Basel/CH)European Journal of Clinical Pharmacology • Archives of Toxicology

LJ-Verlag GmbH & Co. KG (Freiburg i. Br.)Laborjournal

Wissenschaftliche Verlagsgesellschaft mbH Stuttgart (Stuttgart)Arzneimitteltherapie • Medizinischen Monatsschrift für Pharmazeuten

PubPharm (Braunschweig)

MDPI AG (Basel/CH)Toxins

State at printing

Company descriptionsACQ Science GmbH (Rottenburg)The ACQ Science GmbH was founded in summer 2010 and develops, produces and distributes reference materials, so-called in-vitro diagnostics. Our products are used by laboratories in Ger-many and Europe for analyses in toxicology and clinical chemistry.

Security, transparency and a maximum of quality characterize our special working methods, which are focussing on the individual needs of our customers. We offer quality controls for each request: we acquire modifications and special developments in a flexible way and in close cooperation with you. The products of ACQ Science are used where reliability and quality are deciding: in the forensic toxicological field and for clinical applications. Therefore, our stated aim is to create reli-able solutions in cooperation with our customers. This requires mutual trust and a high degree of transparency and enables a long-term partnership. As an ISO certified company, we are always aiming at improving and advancing our products in order to offer you top quality on the market.

Agilent Technologies Sales & Services GmbH & Co.KG (Waldbronn)As a global leader in analytical laboratory technologies, Agilent provides trusted answers to our customers’ most critical questions and challenges. Leveraging more than 50 years of laboratory, clinical, and enterprise level expertise, we produce advanced instruments, software and con-sumables, supported by teams of highly skilled and knowledgeable people. We combine all that to provide the most comprehensive solutions available today. Solutions that produce the most accurate and reliable results as well as optimal scientific, economic, and operational outcomes. Solutions that help customers in biopharma and pharma discover, develop, and manufacture medicines to improve the human condition and quality of life.

16

SPONSORS AND EXHIBITORS

We would like to thank the following sponsors and exhibitors for their great support!

Main sponsorsACQ Science GmbH (Rottenburg)

Agilent Technologies Sales & Services GmbH & Co.KG (Waldbronn)

Industrial symposium • Wednesday, 28 February 12:00–13:00Agilent Technologies Sales & Services GmbH & Co.KG (Waldbronn)

Sponsor pens and writing padsWebers GmbH (Oberhausen)

SponsorBIOLOG Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH (Bremen)

Exhibitors booth numberACQ Science GmbH (Rottenburg) 17Agilent Technologies Sales & Services GmbH & Co.KG (Waldbronn) 32AnaPath Services GmbH (Liestal/CH) 26BIOMOL GmbH (Hamburg) 19Biotrend Chemikalien GmbH (Cologne) 16Bundesinstitut für Risikobewertung (BfR) (Berlin) 8Carl Zeiss Microscopy GmbH (Jena) 15Charles River, Research Models and Services, Germany GmbH (Sulzfeld) 9Data Sciences GmbH (Offenbach) 27Fine Science Tools GmbH (Heidelberg) 25LGC Standards GmbH (Wesel) 18LI-COR Biosciences GmbH (Bad Homburg) 22MDE GmbH (Walldorf) 20Nanion Technologies GmbH (Munich) 11NIPPON GENETICS EUROPE GmbH (Dueren) 1npi electronic GmbH (Tamm) 12OLS OMNI Life Science GmbH & Co KG (Bremen) 14Philip Morris International (Neuchatel/CH) 24PortaCellTech BioSciences GmbH (Göttingen) 29PROMEGA GmbH (Mannheim) 4PromoCell GmbH (Heidelberg) 3Proteintech Europe (Manchester/GB) 10RTC S.p.A. (Pomezia/IT) 28ssniff Spezialdiäten GmbH (Soest) 21Stemcell Technologies Germany GmbH (Cologne) 13TSE Systems GmbH (Bad Homburg) 23

17

FLOOR PLAN OF VENUE AND EXHIBITION AREA

1�� floor1�� floor

Self check-in

1�� floorHS 104Poster exhibition (P88–P273)Media check-inCloakroom

Ground floor

Check-inPoster exhibition (P01–P87)

18

PROGRAMME OVERVIEW • MONDAY, 26 FEBRUARY

HS 006 HS 001 HS 004

10:00–17:00

13:00–16:40 13:00–17:00

p. 25p. 24 p. 26

GeneralPharmacology (DGP)Toxicology (GT)Clinical Pharmacology (DGKliPha)AGAH workshopIndustryPoster sessionVKliPhaForum Young ScientistSocial programme

Advanced Course Toxicology Risikobewertungskonzepte für verschiedene regulatorische Bereiche

Advanced Course Clinical Pharmacology ADME & clinical application

Advanced Course Pharmacology Preclinical drug development

19

PROGRAMME OVERVIEW • TUESDAY, 27 FEBRUARY

HS 011 HS 009 HS 006 HS 001 HS 10408:30–09:30

09:00–10:30 09:00–10:30 09:00–10:30

09:30–10:30

p. 28 p. 29 p. 2910:45–11:00

11:00–11:4511:45–13:00

p. 3012:00–12:45 12:00–12:45 12:00–12:45Meet the company Meet the company Meet the company

p. 31 p. 31 p. 32

p. 14

14:30–16:00

16:15–17:45 16:15–17:45 16:15–17:45 16:15–17:45

p. 33 p. 33 p. 33 p. 3417:45–19:15 17:45–19:15 17:45–19:15

from 19:30

Symposium 1Paul Martini SymposiumNeue Studienkonzepte in der klinischen Entwicklung

Openingceremony

Short presentationsToxicology: Toxic compounds

Plenary I – Gunther Hartmann

Social evening – Science slamForum Young Scientist in the city of Göttingen

Short presentationsPharmacology: G‐protein coupled receptors & cyclic nucleotides

General meeting DGKliPha

12:45–13:30

13:30–14:30Poster session I

General meeting GT

General meeting DGP

Short presentationsToxicology: Genotoxicity/ carcinogenesis I Short presentations

Pharmacology:Epigenetics

Special event: BMBF‐project funding on innovative toxicology for alternatives to animal testing

Get together within the industrial exhibition

p. 56

Short presentationsClinical Pharmacology:Drug discovery

Symposium 2 Endocrine disruptors: Regulatory status

Symposium 3From basic to translation research for novel therapeutics in heart and brain disease

p. 14

Symposium 4Kommunikation (in) der Wissenschaft: Zwischen Selbstmarketing und gesellschaftlichem Dialog

Symposium 5Ethische und rechtliche Probleme bei klinischen Arzneimittelstudien

p. 34

p. 30

p. 27

p. 27

p. 30

p. 32

p. 34p. 34

20

PROGRAMME OVERVIEW • WEDNESDAY, 28 FEBRUARY

HS 011 HS 009 HS 006 HS 001 HS 104 HS 00408:30–09:15

09:00–10:30 09:00–10:30 09:00–10:30 09:00–10:45

p. 3509:15–10:30

p. 35 p. 36 p. 37 p. 46

11:00–11:4512:00–13:00

p. 3912:15–14:30

p. 3913:00–14:00

14:00–15:00 14:00–15:00 14:00–15:00 14:00–15:00p. 46

14:45–17:00

p. 39 p. 40 p. 40 p. 41

15:30–17:00 15:30–17:00 15:30–17:00 15:30–17:00p. 47

p. 41 p. 42 p. 4317:00–17:30

17:15–18:45 17:15–18:45 17:15–18:45 17:15–18:45

p. 42

p. 43 p. 44 p. 44 p. 4418:45–19:15 Award ceremony

19:45–23:30

Symposium 14 Precision medicine in cancer

Symposium 7Mode of action as the basis for risk assessment of the chemical

Symposium 8Regenerative pharmacology

Symposium 10Novel cancer therapies

Short presentations Pharmacology: Ion channels

Short presentations Pharmacology: Central nervous system

AGAH WorkshopFirst-in-human trials: What you need to know III

p. 73

Symposium 6 Current practice and perspectives in CRO oversight in Germany

Industrial symposium

Social eveningRestaurant Bullerjahn

Symposium 11 Non-standard enzymes in xenobiotic metabolism

Symposium 12 Phenotypic drug screens in human tissue platforms

Symposium 13 Organ fibrosis: Mechanisms and therapeutic aspects

AGAH WorkshopFirst-in-human trials: What you need to know I

Short presentationsToxicology: Risk assessment

Short presentationsToxicology: Toxins

General meeting FJW

Plenary II – Ernst Bamberg

AGAH WorkshopFirst-in-human trials: What you need to know II

Poster session II

Short presentations Pharmacology: Cancer pharmacology & treatment

Short presentations Pharmacology: Cardiovascular pharmacology & treatment

Short presentations Clinical Pharmacology: Pharmacokinetics and personalised therapy p. 38

Symposium 9The relevance of the microbiome with regard to pharmacology and toxicology

p. 14

Short presentations Toxicology: Organ toxicology

p. 45

p. 42

21

PROGRAMME OVERVIEW • THURSDAY, 1 MARCH

HS 011 HS 009 HS 006 HS 001 HS 00408:30–09:30

09:00–10:30 09:00–10:30 09:00–10:30

09:30–10:30

p. 48 p. 49 p. 50 p. 5110:45–11:30

11:45–13:15 11:45–13:15 11:45–13:15 11:45–13:00

p. 53p. 52 p. 52 p. 53

13:30–15:00 13:30–15:00 13:30–15:00 13:30–15:00

p. 53 p. 54 p. 54 p. 5515:00–15:30 Poster award ceremony

p. 55

Joint-Symposium 20Joint session of the Dutch and German pharmacology societies

Symposium 22Modern tools and concepts for better understanding metabolism and transport of drugs in our body

Symposium 21Big data

Symposium 18Pharmakologie-historisches Forum

Symposium 15Dieselmotoremissionen: Aktueller Stand der Bewertung mit Schwerpunkt Arbeitsschutz

Symposium 16Targeting cellular calcium handling in health and disease

Short presentationsPharmacology:Membrane transporters

Short presentationsPharmacology:Immunopharmacology Short presentations

Toxicology: Biomarkers

Clinical Pharmacology (DGKliPha)Toxicology (GT)Pharmacology (DGP)

Short presentationsClinical Pharmacology:Clinical studies and pharmacoepidemology

Forum Young ScientistVKliPhaPoster session

Social programme

AGAH workshop

General

Short presentations Toxicology: Genotoxicity/ carcinogenesis II

Joint-Symposium 19 DGP–STS Tumor cell metastasis: Regulating mechanisms and pharmacological targeting

Industry

Plenary III – Jukka Malm p. 52

Symposium 17Pulmonary drug administration (in cooperation with AGAH)

p. 48

22

SPECIAL MEETINGS

Monday, 26 February

10:00–18:00 Prüfungen in der Toxikologie Hs 1.141

12:00–13:00 AK Regulatorische Toxikologie Hs 001

17:00–18:00 Vorstandssitzung der Deutschen Gesellschaft für Hs 006 Pharmakologie (DGP)

17:00–18:30 Vorstandssitzung der Gesellschaft für Toxikologie (GT) Hs 001

18:00–20:30 Treffen der AG Planmäßiger Professoren der Experimentellen undHs 006 Klinischen Pharmakologie und Toxikologie

Tuesday, 27 February

13:00–14:00 AK Carcinogenese Hs 006

18:40–20:20 Mitgliederversammlung der Gesellschaft für Toxikologie (GT)Hs 009

18:40–20:20 Mitgliederversammlung der Deutschen Gesellschaft für Hs 001 Klinische Pharmakologie und Therapie (DGKliPha)

18:40–20:20 Mitgliederversammlung der Deutschen Gesellschaft für Hs 006 Pharmakologie (DGP)

Wednesday, 28 February

08:00–09:00 Mitgliederversammlung des Verbundes der Klinischen .Hs 001 Pharmakologie e. V. (VKliPha)

11:30–13:00 Editorial board meeting in Naunyn-Schmiedebergs Archives of pharmacologyHs 1.141

12:00–12:30 AK Computergestützte Methoden in der ToxikologieHs 001

23

mAbs can have numerous quality attributes that can impact drug safety and/or efficacy. Confidently identifying CQAs is a crucial and challenging step in biotherapeutics development. For all your attribute characterization challenges, Agilent can help you turn your unknowns into answers.

Renowned for accuracy and reliability, Agilent offers a comprehensive set of technologies—instruments, columns, databases, methods, and more—complete solutions so you can confidently handle even your most complex mAb challenges.

For all mAb quality attributes, you need confidence in your answers. You need to be Agilent sure.

© Agilent Technologies, Inc. 2018

SPECIAL MEETINGS

Wednesday, 28 February

12:30–13:30 AK 3RHs 001

13:15–14:00 Präsidiumssitzung und Mitgliederversammlung der Deutschen GesellschaftHs 1.141 für Experimentelle und Klinische Pharmakologie und Toxikologie (DGPT) e. V.

17:00–17:30 Mitgliederversammlung Forum Junge WissenschaftHs 011

Thursday, 1 March

13:30–14:00 AK Biogene ToxineHs 011

2424

SCIENTIFIC PROGRAMME • MONDAY, 26 FEBRUARY

10:00–17:00 Advanced Course Toxicology Hs 001 Risikobewertungskonzepte für verschiedene regulatorische BereicheChair M. Werner (Mannheim)

10:00 Begrüßung W. Aulmann (Monheim)

10:15 Einführung M. Werner (Mannheim)

Risikobewertungen in den Bereichen Biozide, Pflanzenschutzmittel, REACh

10:30 Risikobewertung bei Bioziden – Aggregiertes/kumuliertes Risiko, „SoC-Risiko“, Lebensmittelrückstände (DRA), Risiko von Nutz-/Haustieren V. Ritz (Berlin)

11:00 Risikobewertung im Bereich PSM – Risiko von Nebenstehenden und Anwohnern, Behandlung von Formulierungshilfsstoffen, Verbraucherrisiko, Mehrfachrückstände J. Kaltenhäuser (Berlin)

11:30 Risikobewertungen für Industriechemikalien – Notwendigkeit einer Risikoabschätzung, Verbraucherrisiko, aggregierte/kumulierte Risikoabschätzung unter REACh A. Ahrens (Helsinki/FI)

12:00–13:00 Mittagspause/AK RegTox Mitgliederversammlung & „Braune-Tüte-Lunch“

Risikobewertung von Tierarzneimitteln, Verunreinigungen in Human- arzneimitteln und Medizinprodukten

13:00 Risikobewertung bei Tierarzneimitteln – Verbrauchersicherheit, Warte- zeiten/MRLs, Sekundärexposition bei Haustieren H. van Hattum (Nijmegen/NL)

13:30 Bewertung von (gentoxischen) Verunreinigungen in Humanarzneimitteln, Kreuzkontaminationen mit APIs C. Sehner (Biberach), A. Czich (Frankfurt a. M.)

14:00 Risikomanagement bei Medizinprodukten – von der Risikoanalyse über die Bewertung zur Kontrolle – Einhaltung von Normen zusätzlich zu Anforderungen der neuen MDR H. Scheffler (Schwalbach a. T.)

14:30–15:00 Kaffeepause

2525


Risikobewertungsstrategien bei Nahrungsmittelkontaktmaterialien und Kosmetika

15:00 Risiko von FCMs – SMLs (Specific Migration Limits), beabsichtigte/ unbeabsichtigte Freisetzung in Lebensmittel S. Zellmer (Berlin)

15:30 Risikoabschätzung bei Kosmetika – Referenzwerte ohne Tierversuche, Risiko der Hautsensibilisierung, aggregiertes Risiko von Konservierungsstoffen W. Lilienblum (Hemmingen)

16:00 Podiumsdiskussion mit Fokus auf der Interaktion der regulatorischen Bereiche

13:00–14:40 Advanced Course PharmacologyHs 006 Preclinical drug development – supported by Safety Pharmacology Society (SPS) and German Centre for Cardiovascular Research (DZHK)Chairs W.-H. Zimmermann (Göttingen), F. J. Hock (Dieburg)

13:00 Introduction to safety pharmacology – industry and academia perspective and considerations M. Pannirselvam (Boston, MA/US), W.-H. Zimmermann (Göttingen)

13:10 Tools and techniques for cardiac contractility to support safety pharmacology R. L. Hamlin (Columbus, OH/US)

13:40 Tools and techniques to understand skeletal muscle contractility M. Pannirselvam (Boston, MA/US)

14:10 Cardiovascular safety liabilities in drug development – case studies K. Derakhchan (Lexington, MA/US)

14:40–15:10 Coffee break

via skype15:10 Advanced in vitro models for cardiac safety A. Pointon (Milton Road/GB)

15:40 Target validation by CRISPR-based genome editing C. Noack (Berlin) 16:10 Setting-up screen for new chemical and molecular entities E. Klußmann (Berlin)

2626


13:00–17:00 Advanced Course Clinical PharmacologyHs 004 ADME & clinical applicationChair K. Bestehorn (Ebenhausen)

13:00 Single- and multiple-transfected in vitro cell models for investigating drug transport J. König (Erlangen)

14:00 Impact of drug metabolism in drug development and in clinical drug therapy I. Cascorbi (Kiel)

15:00 Pharmacogenetics of drug transport and drug metabolism J. Brockmöller (Göttingen)

16:00 Physiological pharmacokinetic/pharmacodynamic modelling – modelling of networks in the human body L. Küpfer (Leverkusen)

German Society for Immunology (DGfl)

and the

Italian Society of Immunology, Clinical Immunology and Allergology (SIICA)

10–13 SEPTEMBER 2019MUNICH/DE

II Joint Annual Meeting of the

SAVE THE DATE

© e

ureg

ioco

nten

t l

fot

olia

.com

www.immunology-conference.de

2727

SCIENTIFIC PROGRAMME • TUESDAY, 27 FEBRUARY

08:30–09:30 Short presentationsHs 009 Toxicology – Genotoxicity/carcinogenesis IChairs A. Cartus (Kaiserslautern), C. Henninger (Düsseldorf)

08:30 Chronic angiotensin II-induced hypertension causes oxidative DNA damage1 and an increased mutation frequency in the rat kidney N. Schupp (Düsseldorf), B. Epe, I. Schulz (Mainz), C. Hartmann (Düsseldorf)

08:45 Differentiated and exponentially growing HL-60 and CaCo-2 cells exhibit2 different sensitivity for genotoxic agents in the comet-assay G. Montag, H. Stopper (Würzburg)

09:00 PARP1 protects from benzo[a]pyrene diol epoxide-induced replication stress3 and mutagenicity J. Fischer, T. Zubel, K. Jander, J. Fix, I. Trussina (Konstanz) D. Gebhard (Konstanz, Sigmaringen), J. Bergemann (Sigmaringen) A. Bürkle, A. Mangerich (Konstanz)

09:15 Functional outcomes of distinct base excision repair steps in the context of4 the 5-methylcytosine oxidation pathway N. Kitsera, N. Geier, M. Rossa (Mainz), T. Carell (Munich), A. Khobta (Mainz)

09:30–10:30 Short presentationsHs 009 Toxicology – Toxic compoundsChairs K. Unfried, N. Schupp (Düsseldorf)

09:30 Correlation between genome-wide histone acetylation changes and5 transcriptional repression by the mycotoxin Ochratoxin A E. Limbeck, A. Mally (Würzburg)

09:45 Identification of potent drug candidates for the prevention of cisplatin6 induced neurotoxicity in the model organism C. elegans S. Honnen, A. Wellenberg, L. Weides (Düsseldorf), J. Bornhorst (Nuthetal) B. Crone, U. Karst (Münster), G. Fritz (Düsseldorf)

10:00 The chemical warfare agent sulfur mustard induces chronic senescence in7 mesenchymal stem cells S. Rothmiller (Munich, Konstanz), A. Bürkle (Konstanz), D. Steinritz H. Thiermann, A. Schmidt (Munich)

10:15 Cytochrome P450 and transporter profiling using rapid and versatile 8 MS-based immunoassays F. Weiss, H. S. Hammer, F. F. Schmidt, H. Planatscher, C. Sommersdorf T. O. Joos, O. Poetz (Reutlingen)

2828


09:00–10:30 Short presentationsHs 006 Pharmacology – EpigeneticsChair R. Gilsbach (Freiburg i. Br.), L. C. Zelarayán (Göttingen)

09:00 A context-specific cardiac Wnt nuclear complex modulates the chromatin in9 homeostasis and disease L. M. Iyer (Göttingen), S. Nagarajan (Cambridge/GB), M. Woelfer, E. Schoger M.-P. Zafeiriou, V. Kari, S. T. Pang, T. Weber, J. Herting, T. Fischer F. S.Rathjens, S. Khadjeh, K. Toischer, G. Hasenfuss, C. Noack, S. A. Johnsen L. C. Zelarayán (Göttingen)

09:15 Chromatin compartments dictate establishment of dynamic DNA10 methylation patterns in mouse cardiac myocytes S. Nothjunge, T. G. Nührenberg, B. Grüning (Freiburg i. Br.) S. A. Doppler (Munich), S. Preissl (Freiburg i. Br.; San Diego, CA/US) M. Schwaderer, C. Rommel (Freiburg i. Br.), M. Krane (Munich), L. Hein R. Gilsbach (Freiburg i. Br.)

09:30 Cytokine-responsive enhancers coordinate chromatin structure and gene11 activities at human chemokine loci S.-S. Weiterer, L. Jurida, J. Meier-Sölch, A. Weber, C. Mayr-Buro M. Bartkuhn (Gießen), L. Brant, A. Papantonis (Cologne), M. Kracht (Gießen)

09:45 Cardiac myocyte miR-29 promotes pathological remodelling of the heart by12 activating Wnt signalling Y. Sassi, P. Avramopoulos, D. P. Ramanujam, L. Grüter, S. Werfel, S. Giosele A.-D. Brunner, D. Esfandyari (Munich), A. S. Papadopoulou B. de Strooper (Leuven/BE), N. Hübner (Berlin), R. Kumarswamy T. Thum (Hannover), X. Yin, M. Mayr (London/GB), B. Laggerbauer S. Engelhardt (Munich)

10:00 Drug resistance in chronic myeloid leukemia – global changes after Imatinib13 exposure and impact of miR-212/ABCG2-axis during the onset of resistance M. Kähler, J. Rümenapp, R. Böhm, D. Gonnermann, I. Nagel (Kiel) O. Ammerpohl (Kiel, Ulm), I. Cascorbi, H. Bruckmüller (Kiel)

10:15 Investigation of the prolyl hydroxylase EGLN3 as drug target in ccRCC14 A. Reustle, S. Winter, F. Büttner, P. Leuthold (Stuttgart), S. Rausch J. Hennenlotter, A. Stenzl, J. Bedke (Tübingen) M. Schwab (Stuttgart, Tübingen), E. Schäffeler (Stuttgart)

2929


09:00–10:30 Short presentationsHs 001 Pharmacology – G-protein coupled receptors & cyclic nucleotidesChairs M. Bünemann (Marburg), B. H. Rauch (Greifswald)

09:00 Allosteric ligand induced alteration of mAChR – G-protein complex stability15 O. Ilyaskina (Marburg), H. Lemoine (Düsseldorf), M. Bünemann (Marburg)

09:15 Structural determinants of biased signalling of human CCR2 chemokine16 receptors J. Kaiser, D. Markx, A. Kleinsteuber, L. Hipp, B. Moepps (Ulm)

09:30 Binding mode ensembles determine ligand efficacy at a GPCR17 M. Bermudez (Berlin; Cambridge/GB), A. Bender (Cambridge/GB) G. Wolber (Berlin)

09:45 The signalling lipid sphingosine-1-phosphate regulates gene and protein18 expression of both plasminogen activator inhibitor-1 and tissue factor in differentiated fat cells E. Moritz, V. Witschel, J. Lühr, C. Joseph, A. Böhm, B. H. Rauch (Greifswald)

10:00 Pathologic impact of pseudomonas aeruginosa ExoY in acute lung infection19 B. Schirmer, C. Kloth, A. Munder, J. Rothschuh, R. Seifert (Hannover)

10:15 AMPA-induced L-type VGCC-dependent cGMP signals are predominantly20 generated by NO-GC2 J. Giesen (Bochum), E.-M. Füchtbauer, A. Füchtbauer (Aarhus/DK), E. Mergia D. Koesling, M. Russwurm (Bochum)

09:00–10:30 Short presentationsHs 104 Clinical Pharmacology – Drug discoveryChairs N. Voigt (Göttingen), S. Engeli (Hannover)

09:00 Novel oxime-type acetylcholinesterase reactivators with peripheral binding21 are ineffective in organophosphate poisoning s. nurulain, M. Fatmi, A. Iqbal, S. Malik, S. Ghafoor (Islamabad/PK) K. Musilek, K. Kuca (Hradec Kralov/CZ), G. Petroianu (Miami, FL/US)

09:15 Digiwest® multiplex protein profiling for biomarker discovery, compound22 MoA and mechanistic tox studies in six species G. Erdmann, J. Schneider, E. Breitinger, Y. Beiter, M. F. Templin C. Sachse (Berlin)

09:30 Fucoidan as a natural anticoagulant, antiviral and anti-cancer drug23 A. Zayed (Kaiserslautern; Tanta/EG), T. Hahn, S. Rupp (Stuttgart) R. Krämer (Heidelberg), R. Ulber (Kaiserslautern)

3030


09:45 Protein substitution therapy in transglutaminase 1 deficient skin models:24 topically applied thermoresponsive nanogels successfully mitigate the ARCI phenotype G. Yealland (Berlin), R. Plank (Huddersfield), K. Fuchs, E. Miceli, M. Molina M. Calderón (Berlin), H. C. Hennies (Huddersfield/GB), S. Hedtrich (Berlin)

10:00 Engineered human skeletal muscle from pluripotent stem cell-derived25 myoblasts – a novel pharmacological tool M. Shahriyari, W.-H. Zimmermann, M. Tiburcy (Göttingen)

10:15 Effects of erlotinib on the gene expression of human primary keratinocytes26 from healthy individuals S. Kemski, C. Scholl, T. Bieber, J. C. Stingl (Bonn)

10:30–10:45 Coffee break and industrial exhibition

10:45–11:00 Opening ceremony DGPT & VKliPhaHs 011 Welcome note of the dean of the medical faculty Göttingen H. K. Kroemer (Göttingen)

Welcome note of the conference chairs W.-H. Zimmermann, J. Brockmöller (Göttingen)

Welcome note of the DGPT President M. Schwab (Stuttgart, Tübingen)

11:00–11:45 Plenary lecture I – Clinical PharmacologyHs 011

Chairs M. Schwab (Stuttgart), J. Brockmöller (Göttingen)

11:00 Nucleic acid immunity – recent insight and new therapeutic opportunities G. Hartmann (Bonn)

11:45–13:00 Special eventHs 009 BMBF-project funding on innovative toxicology for alternatives to animal 27 testingChairs S. Matthiesen (Jülich), R. Buesen (Ludwigshafen a. R.)

11:45 Combiomics 2 – analysis of mixture effects of pesticides in vitro28 A. Braeuning (Berlin)

12:00 Systems biology approaches to explain and predict developmental 29 neurotoxicology M. Leist (Konstanz)

3131


12:15 EXITOX-II – development of an animal free testing strategy for the risk30 assessment of inhalable compounds S. Escher, I. Tluczkiewicz, T. Hansen, M. Niehof, J. Knebel, D. Ritter, O. Danov H. Obernolte, S.-F. Schramm (Hannover), J. Koschmann A. Kel (Wolfenbüttel), E. Wingender, C. Meckbach (Göttingen) W. Boomgarden (Emden), K. Sewald (Hannover)

12:30 Accuracy of the prediction of human hepatotoxicity31 J. G. Hengstler, R. Stöber, W. Albrecht (Dortmund), A.-C. Behr, A. Braeuning B. Thorsten, A. Lampen (Berlin), G. Damm (Leipzig), J. Rahnenführer (Dortmund)

12:45 Discussion

12:00–12:45 Meet the companyChair K. Bestehorn (Ebenhausen)Hs 006

The following companies invite you to a short presentation – get an impression of their products and work: Proteintech Europe RTC S.p.A. LGC Standards GmbH PromoCell GmbH TSE Systems GmbH

12:00–12:45 Meet the companyChair W.-H. Zimmermann (Göttingen)Hs 001

The following companies invite you to a short presentation – get an impression of their products and work:

AnaPath Services GmbH Biotrend Chemikalien GmbH Carl Zeiss Microscopy GmbH Charles River, Research Models and Services, Germany GMBH Data Sciences GmbH

3232


12:00–12:45 Meet the companyChair J. Brockmöller (Göttingen)Hs 104

The following companies invite you to a short presentation – get an impression of their products and work:

LI-COR Biosciences GmbH Nanion Technologies GmbH npi electronic GmbH OLS OMNI Life Science GmbH & Co KG PROMEGA GmbH

12:45–13:30 Get together within the industrial exhibitionFoyer (see page 14)

13:30–14:30 Poster session IFoyer (see page 56)

14:30–16:00 Symposium 1 Hs 011 Paul Martini Symposium – neue Studienkonzepte in der klinischen Entwicklung Chairs S. Frings (Grenzach-Wyhlen), K. Bestehorn (Ebenhausen)

14:30 Komplexe Studiendesigns – Dilemma für Ethik-Kommissionen und Behörden T. Sudhop (Bonn)

14:45 Innovative Studiendesigns – Wie bringt man einen bi-spezifischen Antikörper für die Krebsimmuntherapie schnell und sicher zur Zulassung? D. Waterkamp (San Francisco, CA/US)

15:00 Neue Studienkonzepte in der klinischen Entwicklung D. Jäger (Heidelberg)

15:15 Adaptive Studienkonzepte – Erfahrungen aus der Sicht der Pharmaindustrie B. Gaschler-Markefski (Ingelheim a. R.)

15:30 Studienkonzepte bei medikamentösen “Sprunginnovationen” am Beispiel der chronischen Hepatitis C S. Zeuzem (Frankfurt a. M.)

15:45 Diskussion


3333


16:15–17:45 Symposium 2Hs 009 Endocrine disruptors – Regulatory statusChairs U. Gundert-Remy, R. Solecki (Berlin)

16:15 Identifying endocrine disruptors – the new European guidance J. Tarazona (Parma/IT)

16:30 Practicability of testing of ED properties – outcome of the BfR survey V. Ritz (Berlin)

16:45 Further developments of testing – the status of the new OECD guidance document J. Odum (Paris/FR)

17:00 Research needs for identification of endocrine effects G. Degen (Dortmund)

17:15 Discussion

16:15–17:45 Symposium 3Hs 006 From basic to translation research for novel therapeutics in heart and brain diseaseChairs H. Kroemer (Göttingen), R. Nitsch (Münster)

16:15 Modulation of histone deacetylase 4 as a new therapeutic principle in cardiac fatigue J. Backs (Heidelberg)

16:30 Targeting phosphodiesterase 2 in heart and brain A. El-Armouche (Dresden)

16:45 Heart and brain – epigenetic approaches to treat diseases of excitable and non-proliferating cells A. Fischer (Göttingen)

17:00 Controlling neuroinflammation in Alzheimer’s disease M. Heneka (Bonn)

17:15 Discussion

16:15–17:45 Symposium 4 Hs 001 Kommunikation (in) der Wissenschaft — Zwischen Selbstmarketing und gesellschaftlichem Dialog – Forum Young ScientistsChairs K. Lorenz (Essen), K. Metzner (Frankfurt a. M.)

16:15 Tierversuche-Verstehen.de – Erfahrungen mit Transparenz und Kommunikation bei einem emotional beladenen Thema S. Treue (Göttingen)

3434


16:35 Redaktionelle Konzepte in Web & Social Media für junge Wissenschaftler E. Heintz (Munich)

16:55 Wissenschaft online sichtbar machen – Karrierewege durch digitales Selbstmarketing S. Geu (Berlin)

17:15 Podiumsdiskussion

16:15–17:45 Symposium 5 Hs 104 Ethische und rechtliche Probleme bei klinischen ArzneimittelstudienChairs W. E. Haefeli (Heidelberg), C. Wiesemann (Göttingen)

16:15 Wege zu einer angemessenen Information von Teilnehmern klinischer Arzneimittelprüfungen W. E. Haefeli (Heidelberg)

16:30 Zentrale ethische Fragen bei klinischen Arzneimittelprüfungen C. Wiesemann (Göttingen)

17:00 Forschung an Nichteinwilligungsfähigen und andere aktuelle rechtliche Fragen bei klinischen Arzneimittelprüfungen A. Spickhoff (Munich)

17:30 Diskussion

17:45–19:15 General meeting Hs 009 Gesellschaft für Toxikologie (GT)

17:45–19:15 General meetingHs 006 Deutsche Gesellschaft für Pharmakologie (DGP)

17:45–19:15 General meetingHs 001 Deutsche Gesellschaft für Klinische Pharmakologie und Therapie (DGKliPha)

19:30–23:30 Social evening – Forum Junge Wissenschaft Science Slam“Zur alten Brauerei” (see page 14)

3535

SCIENTIFIC PROGRAMME • WEDNESDAY, 28 FEBRUARY

08:30–09:15 Short presentationsHs 009 Toxicology – Risk assessmentChairs A. Mally (Würzburg), V. Lange (Dortmund)

08:30 Common shortcomings of read-across adaptations under the REACH regulation32 J. vom Brocke (Helsinki/FI)

08:45 Cumulative risk assessments should be conducted only on adverse, human33 relevant lead effects of pesticidal active ingredients S. Melching-Kollmuss (Ludwigshafen a. R.), T. Colnot (Casilla/CL) J. Mehta (Abingdon/GB), G. Semino-Beninel (Sophia Antipolis/FR)

09:00 Evaluation of relevance and reliability of experimental data in human health34 risk assessment of pesticides J. Kaltenhäuser, C. Kneuer, P. Marx-Stoelting, L. Niemann, J. Schubert B. Stein, R. Solecki (Berlin)

09:15–10:30 Short presentations Hs 009 Toxicology – ToxinsChairs R. Gerhard (Hannover), K. Ernst (Ulm)

09:15 The recombinant C2IN-C3lim Rho-inhibitor inhibits motility and 35 chemotactic recruitment of monocytic cells ex vivo and in vivo T. Martin, A. Möglich, I. Felix, A. Palmer, S. Denk, S. Paschke M. Huber-Lang, H. Barth (Ulm)

09:30 Inhibition of Clostridium difficile toxins TcdA, TcdB, and CDT by human 36 α-defensin-1 S. Fischer, A.-K. Ückert, A.-K. Mittler (Ulm) P. Papatheodorou (Ulm, Freiburg), C. Hoffmann-Richter, M. Hägele (Ulm) C. Schwan (Freiburg), U. Ziener, M. Müller, A. Kleger (Ulm) K. Aktories (Freiburg), H. Barth (Ulm)

09:45 Foodbourne pathogen Yersinia enterocolitica encodes for a cytotoxic 37 Rho-inactivating glycosyltransferase S. Schneider, K. Aktories, T. Jank (Freiburg)

10:00 Targeting oncogenic Ras signalling by clostridium perfringens toxin TpeL38 P. Papatheodorou (Freiburg, Ulm), B. Schorch, K. Aktories (Freiburg)

10:15 A lipid-binding-loop mediates high-affinity binding and toxicity of botulinum 39 neurotoxin serotypes B, DC, and G D. Stern (Berlin), J. Weisemann (Hannover), A. Le Blanc (Munich) L. von Berg (Berlin), S. Mahrhold (Hannover), J. Piesker, M. Laue (Berlin) P. B. Luppa (Munich), M. Dorner, B. Dorner (Berlin), A. Rummel (Hannover)

3636


09:00–10:30 Short presentationsHs 006 Pharmacology – Cancer pharmacology & treatmentChairs B. Hinz (Rostock), S. Behrends (Braunschweig)

09:00 Opioids support tumor angiogenesis through HIF1α-mediated COX240 expression in estrogen-dependent breast cancer cells A. Schoos, D. Fux (Vienna/AT)

09:15 Members of the Neuropilin axis as novel candidate target genes in41 pancreatic carcinoma H. Borchardt (Leipzig), A. Schulz, M. Muders (Dresden), A. Aigner (Leipzig)

09:30 Statins reverse the effects of activating mutations in the phospholipase42 C-γ2 gene mediating drug resistance in chronic lymphocytic leukemia c. Walliser, T. Merz, T. Ostertag, E. Hermkes, A. Schade, M. Wist P. Gierschik (Ulm)

09:45 Temozolomide induced senescence of glioma cells is activated in the G243 phase and associated with disruption of the E2F1/DP1 complex and repression of MMR and HR D. Aasland, L. Götzinger, N. Berte, M. Tomicic, B. Kaina M. Christmann (Mainz)

10:00 Anticancer efficacy of the cardenolide glycoside Acovenoside A is mediated44 by endosomal EGFR arrest s. Hafner, S. Lang, T. Syrovets, T. Simmet (Ulm)

10:15 Fibroblasts mediate tumor cell death through tunneling nanotubes in45 response to ionizing radiation o. Reiners, A. Schütze, J. Morawitz, C. Reichert D. Waldera-Lupa (Düsseldorf), V. Jendrossek (Essen) K. Stühler (Düsseldorf), K. Pantel (Hamburg), S. Twarock J. W. Fischer, K. Röck (Düsseldorf)

3737


09:00–10:30 Short presentationsHs 001 Pharmacology – Cardiovascular pharmacology & treatmentChairs U. Kintscher (Berlin), F. Friedrich (Hamburg)

09:00 The small Rho-GTPase Rac1 as a potential therapeutic target in46 anthracycline-induced cardiotoxicity c. Henninger, S. Pohlmann, J. Ohlig, M. Kelm (Düsseldorf) M. Merx (Gehrden), G. Fritz (Düsseldorf)

09:15 Regulation and role of the Raf kinase inhibitor protein in ischemic47 cardiovascular diseases C. Schanbacher (Dortmund, Würzburg), C. Mathejka (Dortmund) M. Bieber (Würzburg), F. Langhauser, C. Kleinschnitz (Essen) K. Lorenz (Würzburg, Dortmund)

09:30 The non-steroidal MR-antagonist finerenone induces differential48 cardiomyocytic gene regulation and nuclear cofactor binding J. Grune, N. Beyhoff, E. Smeir, R. Chudek, A. Blumrich, Z. Ban, S. Brix I. R. Betz, M. Schupp, A. Foryst-Ludwig, R. Klopfleisch, P. Stawowy W. Kübler (Berlin), R. Houtman (‘s-Hertogenbosch/NL), P. Kolkhof (Wuppertal) U. Kintscher (Berlin)

09:45 In vivo TBX5 re-expression rescues arrhythmias in TBX5KO mice49 F. S. Rathjens, L. M. Iyer (Göttingen), A. Jungmann, O. Müller (Heidelberg) L. C. Zelarayán, M.-P. Zafeiriou, W.-H. Zimmermann (Göttingen)

10:00 The role of the Rac1 activator Tiam1 in cardiac stress remodelling50 J. van Heuveln, E. Betz, M. Dewenter, J. Backs, T. Wieland C. Vettel (Heidelberg, Mannheim)

10:15 BAY 60-2770 activates two isoforms of nitric oxide sensitive guanylyl cyclase:51 evidence for stable insertion of activator drugs A. Sömmer (Braunschweig), P. Sandner (Wuppertal) S. Behrends (Braunschweig)

3838


09:00–10:30 Short presentationsHs 104 Clinical Pharmacology – Pharmacokinetics and personalised therapyChairs I. Cascorbi (Kiel), M. V. Tzvetkov (Göttingen)

09:00 Predicting apparent passive permeability of Caco-2 and MDCK cell52 monolayers – a mechanistic model K.-U. Goss, K. Bittermann (Leipzig)

09:15 The role of the organic cation transporter OCT1 in the hepatic uptake of53 thiamine and effects of OCT1 polymorphisms on thiamine pharmacokinetics in human O. Jensen, J. Matthaei (Göttingen), J. Müller, S. Oswald (Greifswald) J. Brockmöller, M. V. Tzvetkov (Göttingen)

09:30 Protein abundance of pharmacokinetically relevant transporter proteins54 and metabolizing enzymes along the human intestine and in the liver: a comparative intra-subject study M. Drozdzik (Szczecin/PL), D. Busch, J. Müller (Greifswald), J. Lapczuk J. Grzegolkowska, M. Ostrowski, M. Kurzawski (Szczecin/PL) S. Oswald (Greifswald)

09:45 Added value of diabetes risk genes to the prediction of HbA1c levels in55 patients initiating metformin or sulfonylurea derivatives D. Martono, H. Heerspink, E. Hak, P. Denig, B. Wilffert (Groningen/NL)

10:00 Impact of genomic variation on pharmacokinetics in old age: 56 a quantitative review of age versus genotype related differences C. Dücker, J. Brockmöller (Göttingen)

10:15 Drug-induced falls and potential pharmacogenetic impact in 57 community-dwelling elderly people – results from the ActiFE Ulm study K. S. Just (Bonn), D. Rothenbacher, M. D. Denkinger (Ulm) J. Brockmöller (Göttingen), J. C. Stingl (Bonn)


3939


11:00–11:45 Plenary lecture II – PharmacologyHs 011

Chair W.-H. Zimmermann (Göttingen)

11:00 The evolution of optogenetic – from discovery to biomedical applications E. Bamberg (Frankfurt a. M.)

12:00–13:00 Industrial symposiumHs 006 Agilent Technologies Sales & Services GmbH & Co.KG (Waldbronn)

Agilent SeaHorse: Sensitive, Robust Assay Platform for Analysis of Cell Metabolism and Mitochondrial Toxicity W. Kammerloher, Agilent (Waldbronn)

Agilent LC/MS: From Pathway Identification to in vivo pathway activity monitoring J. Zeiser, Agilent (Waldbronn)

13:00–14:00 Poster session IIFoyer (see page 73)

14:00–15:00 Short presentationsHs 009 Toxicology – Organ toxicologyChairs A. Braeuning (Berlin), H. Hintzsche (Erlangen)

14:00 Colonising 3D skin – a novel test system to study host-microbe skin toxicity58 L. Lemoine, T. Tralau, A. Luch (Berlin)

14:15 Application of the adverse outcome pathway concept for prediction of59 systemic toxicity – Kidney injury due to receptor mediated endocytosis and lysosomal overload as a case study S. Jarzina, P. Reiser (Würzburg), B. Ellinger (Hamburg), S. Di Fiore (Aachen) A. Mally (Würzburg)

14:30 The aryl hydrocarbon receptor (AHR) protects keratinocytes against the60 ultraviolet A (UVA)-induced phototoxicity of 6-formylindolo[3,2-b]carbazole (FICZ) K. M. Rolfes (Düsseldorf), M. Nakamura (Düsseldorf; Nagoya/JP) J. Krutmann, T. Haarmann-Stemmann (Düsseldorf)

14:45 Tubulo-interstitial cross talk modulates the impact of ochratoxin A (OTA) on61 renal epithelial cells M.-C. Schulz, M. Gekle, G. Schwerdt (Halle a. d. S.)

4040


14:00–15:00 Short presentationsHs 006 Pharmacology – Central nervous system pharmacologyChairs M. Schwaninger (Lübeck), M.-P. Zafeiriou (Göttingen)

14:00 Brain endothelial Gαq/11 signalling affects CO2-induced breathing and62 anxiety-like behavior by blood flow regulation J. Wenzel, J. Assmann (Lübeck), J. Sedlacik, J. Fiehler (Hamburg) M. Wegmann (Borstel), S. Offermanns (Bad Nauheim) M. Schwaninger (Lübeck)

14:15 Aβ oligomer eliminating D-enantiomeric peptides enhance cognition and63 impede neurodegeneration in transgenic Alzheimer’s disease mouse models even by oral application D. Willbold (Jülich, Düsseldorf)

14:30 Effects of Zika virus on gene expression64 D. Tabari, C. Scholl (Bonn), E. Hildt (Langen), J. C. Stingl (Bonn)

14:45 Functional maturation of hippocampal synapses depends on the 65 sodium-activated potassium channel Slack L. Matt, A. E. Bausch, P. Ruth, R. Lukowski (Tübingen)

14:00–15:00 Short presentationsHs 001 Pharmacology – Ion channelsChairs D. Dobrev (Essen), T. Gudermann (Munich)

14:00 Store-operated (SOCE) and receptor-operated Ca2+ entry (ROCE) in STIM1/266 and TRPC1/3/6 deficient precapillary pulmonary arterial smooth muscle cells (PASMC) and primary lung fibroblasts L. Bendiks, D. Stickel, T. Gudermann (Munich), S. Feske (New York, NY/US) A. Dietrich (Munich)

14:15 Identification of OCaR1 as a gatekeeper of lysosomal-granular Ca2+ release67 and regulated exocytosis V. Tsvilovskyy, U. Kriebs, A. Bach (Heidelberg), A. Jha (Bethesda, MD/US) A. Wirth (Heidelberg), C. Grimm (Munich), U. Wissenbach (Homburg) K. Zimmermann (Bonn), P. Weissgerber (Homburg), D. Vogt, D. Schumacher J. Camacho Londoño (Heidelberg), C. Wahl-Schott (Munich) A. Pfeifer (Bonn), M. Biel (Munich), P. Lipp, V. Flockerzi (Homburg) S. Muallem (Bethesda, MD/US), M. Freichel (Heidelberg)

14:30 Specific functions of Slack potassium channels in peripheral neuropathic pain68 K. Metzner, C. Flauaus (Frankfurt a. M.), A. E. Bausch (Tübingen) C. Stoetzer (Hannover), P. Ruth (Tübingen), A. Leffler (Hannover) R. Lukowski (Tübingen), A. Schmidtko, R. lu (Frankfurt a. M.)

4141


14:45 Abnormal cellular electrophysiology and calcium handling in iPSC-CMs from a69 patient with tetralogy of Fallot R. Dülk, F. E. Mason (Göttingen), S. Schönhals (Berlin), D. Dobrev (Essen) W.-H. Zimmermann (Göttingen), S. Rickert-Sperling (Berlin) N. Voigt (Göttingen)

14:00–15:00 Symposium 6 Hs 104 Current practice and perspectives in CRO oversight in GermanyChairs K. Mettke (Bonn), F. Hundt (Berlin)

14:00 Actual situation in Germany M. Henning (Munich)

14:20 The view of the BfArM (and thoughts from the EU Inspectors Group) K. Mettke (Bonn)

14:40 How to do in daily practice S. Mikus (Berlin)


15:30–17:00 Symposium 7Hs 009 Mode of action as the basis for risk assessment of the chemical carcinogensChairs D. Schrenk, A. Cartus (Kaiserslautern)

15:30 Definition, mode of action and classification of carcinogens – consequences for risk assessment A. Boobis (London/GB)

15:50 Mode of action as the basis for risk assessment of chemical carcinogens: the case of glyphosate H. Greim (Munich)

16:10 Mode of action as the basis for risk assessment of chemical carcinogens: the case of formaldehyde U. Gundert-Remy (Berlin)

16:30 Mode of action as the basis for risk assessment of chemical carcinogens: the case of furan D. Schrenk (Kaiserslautern)

16:50 Discussion

4242


15:30–17:00 Symposium 8Hs 006 Regenerative pharmacologyChairs T. Wieland (Mannheim), U. Ravens (Freiburg i. Br.)

15:30 Tissue engineered heart repair – the Hamburg experience T. Eschenhagen (Hamburg)

15:50 Tissue engineered heart repair – the Göttingen experience W.-H. Zimmermann (Göttingen)

16:10 Antifibrotic therapy with non-coding RNA S. Engelhardt (Munich)

16:30 Overcoming the regeneration block by antifibrotic therapy with small molecules M. Zeisberg (Göttingen)

16:50 Discussion

15:30–17:00 Symposium 9Hs 001 The relevance of the microbiome with regard to pharmacology and toxicology – Forum Young Scientists Chairs C. Klenk (Zurich/CH), E. E. Bankoglu (Würzburg)

15:30 Is the microbiome relevant to pharmacology and toxicology? P. Holzer (Graz/AT)

16:00 Flagellin hypervariable domain structure contributes to either pathobiotic probiotic properties of commensal Escherichia coli strains J. Frick (Tübingen)

16:20 A metabolomic approach to investigate changes of the gut microbiome C. Behr (Ludwigshafen a. R.)

16:40 Efficacy, safety and regulatory aspects of fecal microbiota transfer M. Vehreschild (Cologne)

17:00–17:30 General meetingHs 011 Forum Junge Wissenschaft

4343


15:30–17:00 Symposium 10Hs 104 Novel cancer therapiesChairs A. Mackensen (Erlangen), J. Brockmöller (Göttingen)

15:30 The CART principle – from discovery and basic principles to clinical approval G. Groß (Kiryat Shmona/IL)

16:10 Current status and perspectives in immunotherapeutic strategies in cancer A. Mackensen (Erlangen)

16:50 Discussion


17:15–18:45 Symposium 11Hs 009 Non-standard enzymes in xenobiotic metabolismChairs E. Maser (Kiel), D. Lang (Wuppetal)

17:15 Carbonyl reductases/steroid dehydrogenases – biology, classification, and implication in drug metabolism and detoxification E. Maser (Kiel)

17:35 Human Aldo-Keto reductases – steroid hormone action and polycyclic aromatic hydrocarbon activation T. Penning (Philadelphia, PA/US)

17:55 Highly variable expression of CYP1A1 in human liver and impact on pharmacokinetics of drugs in humans D. Lang (Wuppertal)

18:15 The mitochondrial Amidoxime Reducing Component (mARC) involved in detoxification of N-hydroxylated structures B. Clement (Kiel)

18:35 Discussion

4444


17:15–18:45 Symposium 12Hs 006 Phenotypic drug screens in human tissue platformsChairs W.-H. Zimmermann (Göttingen), S. Engelhardt (Munich)

17:15 In vitro assessments of drug-induced neuronal modulation – comparing and contrasting human and rodent models B. Bader (Rostock)

17:35 Tumor organoids for drug screening and target validation P. Guye (Zurich/CH)

17:55 Engineered heart tissue as comprehensive in vitro proarrhythmia assay A. Hansen (Hamburg)

18:15 Drug screens, disease modelling, and target validation in engineered heart and skeletal muscle M. Tiburcy (Göttingen)

18:35 Discussion

17:15–18:45 Symposium 13Hs 001 Organ fibrosis – Mechanisms and therapeutic aspectsChairs S. Lutz (Göttingen), E. Dworatzek (Berlin)

17:15 Pericytes in organ fibrosis R. Kramann (Aachen)

17:35 Mechanisms in lung fibrosis M. Schmidt (Groningen/NL)

17:55 Mechanisms in heart fibrosis E. Zeisberg (Göttingen)

18:15 Novel targets for the treatment of fibrosis – focus on systemic sclerosis J. Distler (Erlangen)

18:35 Discussion

17:15–18:45 Symposium 14Hs 104 Precision medicine in cancerChairs M. Schwab (Stuttgart), I. Cascorbi (Kiel)

17:15 Molecular characterization in oncology – perspectives and future directions S. Fröhling (Heidelberg)

4545


17:40 Regulatory challenges in biomarker-based cancer drug therapy N. Benda (Bonn)

18:05 Imaging tumor heterogeneity J. Disselhorst (Tübingen)

18:30 Discussion 18:45–19:15 Award ceremonyHs 009 • Young Scientist Toxicology Merck Award, sponsored by Merck KGaA, Darmstadt • Buchheim-Preis

19:45–23:30 Social eveningRestaurant (see page 14)Bullerjahn

The European Society of Toxicology In Vitro (ESTIV)

German Toxicology Society (GT)The Center for Alternatives to

Animal Testing – Europe (CAAT-Europe)

15–18 October 2018 I Estrel Hotel Berlin www.estiv2018.com

Abstract deadline: 17 June 2018

20th International Congress on In Vitro Toxicology

© h

ywar

ds l

Foto

lia.c

om

4646

AGAH WORKSHOP • WEDNESDAY, 28 FEBRUARY

This workshop addresses young scientists working in basic pharmacological research and other colleagues involved in biomedical research who would like to know more about early phase clinical development. First-in-human trials will be the focus of this workshop. Non-clinical prerequisites, ethical and regulatory requirements, starting dose, dose escalation rules and stopping criteria, design aspects and clinical conduct, as well as pros and cons of integrated protocols will be addressed.

09:00–10:45 First-in-human trials – what you need to know IHs 004

Chairs G. Wensing (Wuppertal), K. Breithaupt-Grögler (Frankfurt a. M.)

09:00 Welcome and introduction G. Wensing (Wuppertal)

09:05 What is a first-in-human trial and what is so special about it? J. Rengelshausen (Aachen)

09:30 Setting the stage – the revised EMA guideline on early phase clinical trials K. Breithaupt-Grögler (Frankfurt a. M.)

10:00 Which answers do we need from non-clinical pharmacology and toxicology prior to the first human exposure? S. Plassmann (Basel/CH)

10:45–12:15 Break for plenary lecture GPTS

12:15–14:30 First-in-human trials – what you need to know IIHs 004

Chairs B. Schug (Oberursel), J. Rengelshausen (Aachen)

12:15 How to derive the human starting dose? S. Plassmann (Basel/CH)

13:00 Integrated protocols – the art of combining several questions into one well-designed trial C. Friedrich (Wuppertal)

13:45 Clinical conduct of a first-in-human trial W. Timmer (Gauting)

14:30–14:45 Break

4747

AGAH WORKSHOP • WEDNESDAY, 28 FEBRUARY

14:45–17:00 First-in-human trials – what you need to know IIIHs 004

Chair B. Schug (Oberursel), J. Rengelshausen (Aachen)

14:45 Challenges in the ethical approval of FIH trials I. Wessler (Mainz)

15:30 Dose escalation and stopping rules in single and multiple ascending dose parts of a FIH trial F. Donath (Erfurt)

16:15 Wrap-up and case study ‘FIH trials in healthy volunteers – a ten years’ review‘ G. Wensing (Wuppertal)

4848

SCIENTIFIC PROGRAMME • THURSDAY, 1 MARCH

08:30–09:30 Short presentationsHs 009 Toxicology – Genotoxicity/carcinogenesis IIChairs M. Christmann (Mainz), A. Mangerich (Konstanz)

08:30 The link between obesity, weight loss and DNA damage70 E. E. Bankoglu, C. Arnold, A. Soliman, F. Seyfried, H. Stopper (Würzburg)

08:45 Formation of DNA-adducts of α- and β-asarone in vitro71 S. Stegmüller, A. Cartus, D. Schrenk (Kaiserslautern)

09:00 Fate of micronuclei – current knowledge and novel approaches72 H. Hintzsche (Würzburg, Erlangen), H. Stopper (Würzburg)

09:15 Impact of a suppressed Insulin/IGF signalling by OSI-906 in the BALB/c 3T373 cell transformation assay D. Hölzer, C. Leovsky, J. Boerner, L. Szimmtenings (Jena) M. Ristow (Zurich/CH), M. Glei, R. Thierbach (Jena)

09:30–10:30 Short presentationsHs 009 Toxicology – BiomarkersChairs E. Richling (Kaiserslautern), S. Honnen (Düsseldorf)

09:30 Urinary background excretion of acrylamide biomarkers74 K. Gömpel, T. Bakuradze, G. Eisenbrand, E. Richling (Kaiserslautern)

09:45 Identification and replication of the interplay of four genetic high risk75 variants for urinary bladder cancer S. Selinski, M. Blaszkewicz, K. Ickstadt (Dortmund) H. Gerullis (Oldenburg, Neuss), T. Otto (Neuss), E. Roth F. Volkert (Wittenberg), D. Ovsiannikov (Dortmund, Koblenz) O. Moormann (Dortmund), G. Banfi, P. Nyirady (Budapest/HU) S. H. Vermeulen (Nijmegen/NL), M. Garcia-Closas (Bethesda, MD/US) J. D. Figueroa (Edinburgh/GB), A. Johnson (Burlington, VT/US) M. R. Karagas (Hanover, NH/US), M. Kogevinas (Madrid, Barcelona/ES) N. Malats (Madrid/ES), M. Schwenn (Augusta, GA/US), D. T. Silverman S. Koutros, N. Rothman (Bethesda, MD/US), L. A. Kiemeney (Nijmegen/NL) J. G. Hengstler, K. Golka (Dortmund)

10:00 Time- and concentration-dependent DNA adduct formation after76 incubation of primary rat hepatocytes with estragole R. Schulte-Hubbert, S. Stegmüller, D. Schrenk (Kaiserslautern)

10:15 Formation of N-(2,3-dihydroxypropyl)-valine in hemoglobin by exposure to77 a glycidyl ester-rich vegetable fat in humans B. Monien, J. Hielscher, T. Kaufholz, H. Mielke, K. Abraham; A. Lampen (Berlin)

4949


09:00–10:30 Short presentationsHs 006 Pharmacology – ImmunopharmacologyChairs D. Neumann (Hannover), T. Meyer (Göttingen)

09:00 Anti-inflammatory role of myeloid-derived suppressor cells in asthma in78 vivo S. Kolahian, N. Nowroozilarki, H. Halit Öz, C. Schroth (Tübingen) A. Ali Shahbazfar (Tabriz/IR), M. Glück, J. S. Antony, M. S. D. Kormann A. Hector, B. Nürnberg, D. Hartl (Tübingen)

09:15 Antimicrobial endotoxin-neutralizing peptides promote keratinocyte79 migration and accelerate wound healing in vivo A. Pfalzgraff (Berlin), S. Bárcena-Varela (Pamplona/ES), L. Heinbockel K. Brandenburg (Borstel), G. Martinez de Tejada (Pamplona/ES) G. Weindl (Berlin)

09:30 Role of the upstream open reading frame (uORF) in the human inducible80 nitric oxide synthase (iNOS) mRNA and the influence of the nonsense mediated mRNA decay (NMD) on iNOS expression F. Gather (Mainz), K. Schmitz, K. Koch (Frankfurt a. M.), A. Pautz H. Kleinert (Mainz)

09:45 Fine-tuning chemokine expression by a SIN3A-associated Pol II-complex81 J. Meier-Sölch, L. Jurida, A. Weber, M. Bartkuhn (Gießen) T. Braun (Bad Nauheim), U. Linne (Marburg), M. Kracht (Gießen)

10:00 The histamine H4-receptor affects experimental colitis due to its functional83 expression on epithelial cells of the mouse colon K. Bittkau, L. Bringmann, D. Bösche, R. Isaev, B. Schirmer, R. Seifert D. Neumann (Hannover)

10:15 The PAR4 thrombin receptor supports wound-healing responses in dermal82 fibroblasts under high glucose conditions A. Fender (Münster), K. Schrör (Düsseldorf)

5050


09:00–10:30 Short presentationsHs 001 Pharmacology – Membrane transportersChairs A. T. Nies (Stuttgart, Tübingen), J. König (Erlangen)

09:00 Establishment and validation of competitive counterflow as a method to84 detect substrates of OATP2B1 A. Schäfer, C. Ferreira, H. E. Meyer zu Schwabedissen (Basel/CH)

09:15 New insights of the intestinal localization of the organic anion transporting85 polypeptide 2B1 (OATP2B1) M. Keiser, J. Müller, C. Wildberg, L. Kaltheuner, L. I. Partecke C.-D. Heidecke, S. Oswald (Greifswald)

09:30 Sodium-dependent organic anion transporter SOAT (SLC10A6)86 Genetic variants in men and lessons from the Slc10a6−/− knockout mouse J. Bennien, K. Bakhaus, T. Fischer, D. Fietz, M. Hartmann, M. Bergmann A. Sánchez-Guijo, S. A. Wudy, J. Geyer (Gießen)

09:45 Opioids as substrates and inhibitors of the geneticly polymorphic organic87 cation transporter OCT1 – What comes after tramadol, codeine, and morphine? M. J. Meyer, V. Neumann, K. Jobst, J. Brockmöller M. V. Tzvetkov (Göttingen)

10:00 Alternative polyadenylation of ABC-transporters – consequences in88 posttranscriptional regulation and transporter mediated pharmacoresistances O. Bruhn, M. Lindsay, K. Drerup, F. Wiebel, C. Röder, I. Cascorbi (Kiel)

10:15 Specific inhibition of MRP4/ABCC4 attenuates integrin αIIbβ3 activation in89 platelets and affects the transport of pro-inflammatory mediators R. Wolf, S. Grammbauer, A. Böhm, G. Jedlitschky, B. H. Rauch (Greifswald)

5151


09:00–10:30 Short presentationsHs 004 clinical pharmacology – Clinical studies and pharmacoepidemologyChairs K. Bestehorn (Ebenhausen), G. Wensing (Wuppertal)

09:00 Relationship between heart failure, concurrent chronic obstructive90 pulmonary disease and beta-blocker use – a Danish nationwide cohort study M. sessa, A. Mascolo (Napoli/IT), R. N. Mortensen M. P. Andersen (Aalborg/DK), G. M. C. Rosano (London/GB), A. Capuano F. Rossi (Napoli/IT), G. Gislason, H. Enghusen-Poulsen (Copenhagen/DK) C. Torp-Pedersen (Aalborg/DK)

09:15 Decreased serum sphingosine-1-phosphate concentrations in subjects91 taking aspirin – association analyses with blood cell-related parameters in the study of health in Pomerania cohort E. Moritz, N. Friedrich (Greifswald), E. Schwedhelm (Hamburg), M. Bahls S. Groß (Greifswald), G. Daum (Hamburg), S. B. Felix, M. Dörr B. H. Rauch (Greifswald)

09:30 A cocktail study to assess pharmacokinetic interactions of acute ethanol92 intake C. Trueck (Cologne), M. Gazzaz (Cologne; Makkah/SA) M. Kinzig (Nuremberg, Cologne), E. Schäffeler (Tübingen, Stuttgart) M. Jübner, C.-h. Hsin, X. Li, M. Taubert, J. Iltgeb-Breburda, D. Kraus C. Queckenberg, M. Stoffel (Cologne), M. Schwab (Tübingen, Stuttgart) F. Sörgel (Nuremberg), U. Fuhr (Cologne)

09:45 Glatiramer acetate, but not other conventional treatments for multiple93 sclerosis, directly alters platelet function and thrombin generation L. Schüngel, S. Eichler, S. G. Meuth, K. Göbel, B. E. Kehrel (Münster)

10:00 Descriptive analysis of spontaneous reports contained in the adverse drug94 reaction database of the Federal Institute for Drugs and Medical Devices in Germany D. Dubrall, M. Schmid, J. C. Stingl, N. Paeschke, B. Sachs (Bonn)

10:15 Severe reduction in tacrolimus concentrations with concomitant95 metamizole (dipyrone) therapy in five transplant patients A. Sigaroudi, T. F. Mueller, A. Jetter, G. Kullak-Ublick, S. Weiler (Zurich/CH)


5252


10:45–11:30 Plenary lecture III – ToxicologyHs 011Chair H. Barth (Ulm)

10:45 10 years of REACH – looking back and looking forward J. Malm (Helsinki/FI)


11:45–13:15 Symposium 15 Hs 009 Dieselmotoremissionen – aktueller Stand der Bewertung mit Schwerpunkt ArbeitsschutzChairs H. Drexler (Erlangen), T. Gebel (Dortmund)

11:45 Grenzwertabteilung am Arbeitsplatz T. Gebel (Dortmund)

12:05 Zelluläre Effekte von Dieselrußbestandteilen S. Schmitz-Spanke (Erlangen)

12:25 Belastungsbiomonitoring zur Qualifizierung der Exposition T. Göen (Erlangen)

12:45 Bewertung des Lungenkrebs durch DMW im deutschen Berufskrankheitenrecht H. Drexler (Erlangen)

13:05 Diskussion

11:45–13:15 Symposium 16Hs 006 Targeting cellular calcium handling in health and diseaseChairs N. Voigt (Göttingen), J. Kockskämper (Marburg)

11:45 Redox regulation of calcium channels – from CRAC to MCU C. Gibhardt (Göttingen)

12:05 Dynamic mitochondrial calcium movement in ventricular cardiomyocytes E. Bertero (Würzburg)

12:25 Regulation of calcium-activated potassium channels in vascular smooth muscle cells T. Wieland (Mannheim)

12:45 Regulation of calcium-activated potassium channels in atrial cardiomyocytes D. Dobrev (Essen)

13:05 Discussion

5353


11:45–13:15 Symposium 17Hs 001 Pulmonary drug administration (in cooperation with AGAH)Chairs B. Schug (Oberursel), G. Wensing (Wuppertal)

11:45 Pulmonary biopharmaceutics – key properties governing local absorption of an inhaled medicine P. Bäckman (Kent/GB)

12:10 Drug inhalation – impact of pulmonary diseases on pulmonary and systemic disposition J. M. Borghardt (Ingelheim a. R.)

12:35 Measurements to assess efficacy of inhaled drugs in early development H. Watz (Grosshansdorf)

13:00 Discussion

11:45–13:00 Symposium 18 Hs 004 Pharmakologie-historisches ForumChairs A. Philippu (Innsbruck/AT), G. Schmidt (Göttingen)

11:45 Einleitung96 A. Philippu (Innsbruck/AT)

11:55 Ludwig Lendle – Leben und Wirken – persönliche Erinnerungen97 G. Schmidt (Göttingen)

12:40 Diskussion und Schlusswort


13:30–15:00 Symposium 19 – Joint Session DGP – Gesellschaft für Signaltransduktion (STS)Hs 009 Tumor cell metastasis – Regulating mechanisms and pharmacological targetingChairs K. Giehl (Gießen), D. Neumann (Hannover)

13:30 Altered metastatic capacity in breast cancer hybrid cells R. Hass (Hannover)

13:55 Influencing melanoma metastasis by inhibition of MIA A. K. Bosserhoff (Erlangen)

14:20 The hepatic micromilieu as regulatory determinant of liver metastasis of pancreatic cancer S. Sebens (Kiel)

14:45 Exploiting the EZH2-Gata6 axis in pancreatic cancer metastasis E. Heßmann (Göttingen)

5454


13:30–15:00 Symposium 20Hs 006 Joint session of the Dutch and German pharmacology societiesChairs S. Lutz (Göttingen), M. Schmidt (Groningen/NL)

13:30 Peptides modulating protein interactions C. Ottmann (Eindhoven/NL)

13:50 Breaking protein aggregation in the brain – from basic concepts to translation C. Griesinger (Göttingen)

14:10 From structure and function to allosteric targeting of LRRK2-mediated Parkinson‘s disease A. Kortholt (Groningen/NL)

14:30 Allosteric targeting of calcium release channels S. Lehnart (Göttingen)

14:50 Discussion

13:30–15:00 Symposium 21Hs 001 Big dataChairs D. Schmidl, M. Bauer (Vienna/AT)

13:30 Advancing genomic medicine – the impact of genome-wide sequencing on clinical management of rare neuromuscular disorders W. M. Schmidt (Vienna/AT)

13:55 Identification of clinically relevant clusters in large-scale routine radiology data J. Hofmanninger (Vienna/AT)

14:20 Biobanks – promoting research quality by standardised preanalytics H. Haslacher (Vienna/AT)

14:45 Discussion

5555


13:30–15:00 Symposium 22Hs 004 Modern tools and concepts for better understanding metabolism and transport of drugs in our bodyChairs U. M. Zanger (Stuttgart), M. V. Tzvetkov (Göttingen)

13:30 Intracellular drug bioavailability – a new predictor of transport and metabolism dependent drug disposition and intracellular target engagement P. Artusson (Uppsala/SE)

14:00 The interplay of nuclear receptors and drug transporters H. E. Meyer zu Schwabedissen (Basel/CH)

14:30 Regulation of drug metabolizing enzymes and transporters by microRNAs: Role of genetic and nongenetic factors U. M. Zanger (Stuttgart)

15:00–15:30 Poster award ceremony & closingHs 009

We would like to invite all abstract authors to participate. The following awards will be given:

Toxicology • GT-Toxicology Preis, sponsored by the Society of Toxicology and the journal „Toxicology“ • GT-Poster award • GT-Award for the best oral presentation • GT-Toxins award for the best poster in the section “Biogene Toxine” sponsored by the Journal “Toxins” (Basel)

Pharmacology • Poster awards

5656

POSTER SESSION I • TUESDAY, 27 FEBRUARY

13:30–14:30 Poster session IPosters should be mounted by Monday or Tuesday morning and be removed on Wednesday by 17:00 at the latest. The presenting authors must be present during the poster session I. Please note the hints for poster presentations on page 12.

Pharmacology – Endocrine pharmacologyChair R. Lukowski (Tübingen)

p01 Differential regulation of the c-fos gene promoter by dual leucine zipper kinase (DLK) K. Köster, J. E. Duque Escobar, E. Oetjen (Hamburg, Kiel, Lübeck)

p02 IGF-1-induced expression of the circadian gene BMAL-1 in temperature-synchronised hypothalamic cells A. Breit, J. Schredelseker, T. Gudermann (Munich)

p03 Hypothalamic akyne-oleate signal is decreased by high fat feeding but normalised when mice were treated with Telmisartan E. Rawish, L. Nickel, I. Stölting (Lübeck), L. Kuerschner (Bonn) W. Raasch (Lübeck)

p04 Competitive inhibition of calcineurin by cyclosporine, tacrolimus and the dual leucine zipper kinase (DLK) J. E. Duque Escobar (Hamburg, Kiel, Lübeck) T. Lemcke (Hamburg) E. Oetjen (Hamburg, Kiel, Lübeck)

p05 Influence of ataxin-2 on the function of pancreatic beta cells F. Mammes (Münster), J. Canet-Pons, G. Auburger (Frankfurt a. M.) M. Düfer (Münster)

p06 Statins inhibit insulinotropic effects of chenodeoxycholic acid by interacting with the farnesoid-X-receptor T. Hoffmeister (Münster), J. Kaiser, G. Drews (Tübingen) M. Düfer (Münster)

p07 Gender-specific alterations of bile acid homeostasis in Non-Alcoholic Fatty Liver Disease (NAFLD) M. Haag (Stuttgart), J. Tevini, A. Feldman, S. K. Eder T. K. Felder (Salzburg/AT), C. Datz (Oberndorf; Salzburg/AT) K. Klein, S. Winter, U. M. Zanger, O. Burk (Stuttgart) M. Schwab (Stuttgart, Tübingen), E. Aigner (Salzburg/AT)

p08 The transcription factor isoforms inducible cAMP early repressor (ICER) and small ICER (smICER) demonstrate distinct differences of binding partners K. Grimm, M. D. Seidl, A. Sternberg, S. Hamer, S. König F. U. Müller (Münster)

5757


Pharmacology — G-protein coupled receptors IChair V. Nikolaev (Hamburg)

p09 Histamine H1 receptors are sensors for fluid shear stress in the endothelium U. Storch, S. Erdogmus, L. Danner (Munich) A. Wirth (Heidelberg, Bad Nauheim) S. Offermanns (Bad Nauheim, Frankfurt a. M.) T. Gudermann, M. Mederos y Schnitzler (Munich)

p10 Structural determinants for mechanosensitvity of Histamine H1 receptors S. Erdogmus, U. Storch, L. Danner, M. Winter (Munich) N. Ziegler (Würzburg), C. Hoffmann (Jena), T. Gudermann M. Mederos y Schnitzler (Munich)

p11 Analysis of the cellular signalling of natural occurring rare genetic variants potentially influencing the course of sepsis A. Winkler, B. Moepps (Ulm)

p12 MOR-HA knock-in mouse – a new tool to study µ-opioid receptor regulation and expression S. Fritzwanker, S. Schulz, A. Kliewer (Jena)

p13 Lycorine modifies the response to activation of NK1 receptors in HEK293 cells in vitro T. Plötz, C. Thomaßen, A. Aigner, G. Abraham, R. Regenthal (Leipzig)

p14 Analysis of GPCR phosphorylation and interaction with GRK’s R. Steinborn, E. Miess, S. Schulz (Jena)

p15 Characterization of the interaction of the Raf kinase inhibitor protein (RKIP) with G protein coupled receptor kinases T. Maimari (Dortmund), C. Krasel, M. Bünemann (Marburg) K. Lorenz (Dortmund, Würzburg, Essen)

p16 Investigation of the 3D architecture and the activation properties of the orthosteric binding pocket of muscarinic receptors M. Kauk (Würzburg), M. Bermudez (Berlin), J. Klöckner N. Yurdagül-Hemmrich, U. Zabel, U. Holzgrabe (Würzburg) G. Wolber (Berlin), C. Hoffmann (Würzburg, Jena)

5858


Pharmacology – Cardiovascular pharmacology & treatment IChair L. Hein (Freiburg i. Br.)

p17 Sex-specific regulation of collagen I and III expression by 17β-Estradiol in cardiac fibroblasts – role of estrogen receptors E. Dworatzek, S. Mahmoodzadeh, C. Schriever, K. Kusumoto, L. Kramer D. Fliegner (Berlin), Y.-K. Leung, S.-M. Ho (Cincinnati, OH/US) W.-H. Zimmermann, S. Lutz (Göttingen), V. Regitz-Zagrosek (Berlin)

p18 Cardiac repair with engineered heart tissue from human induced pluripotent stem cells f. Weinberger, M. Reinsch, D. Köse, L. Castro, S. Pecha, A. Hansen T. Eschenhagen (Hamburg)

p19 Histamine H2-receptors affect atrial function during hypoxia and reoxygenation in transgenic mice b. au, U. Gergs, J. Neumann (Halle a. d. S)

p20 Overexpression of PP2C in mice alters cardiac response to hypoxia T. bruns, U. Gergs, J. Neumann (Halle a. d. S)

p21 Mechanisms of cardiac hypertrophy in PP2AxPP5 double transgenic mice F. Köpp, M. Dörner, J. Runte, U. Gergs, J. Neumann (Halle a. d. S)

p22 Co-overexpression of protein phosphatases 2A and 2C in a transgenic mice leads to altered systolic and diastolic heart function and increased relative heart weight M. Jaron, U. Gergs, J. Neumann (Halle a. d. S)

p23 Influence of aging on cardiac hypoxia in PP2A overexpressing mice M. Dörner, U. Gergs, J. Neumann (Halle a. d. S)

p24 Ferric chloride-induced arterial thrombosis model in pre-clinical drug development L. A. A. Neves, O. Tiniakova, H. Wang, J. Huang, P. B. Senese M. R. Gralinski (Chicago, IL/US), F. J. Hock (Dieburg)

5959


Pharmacology – Cardiovascular pharmacology & treatment IIChair A. El-Armouche (Dresden)

p25 Dapagliflozin reduces platelet activation and atherosclerosis C. Kohlmorgen, K. Feldmann, S. Twarock, S. Hartwig, S. Lehr C. Helten (Düsseldorf), P. Keul (Essen), A. Polzin, M. Kelm (Düsseldorf) B. Levkau (Essen), J. W. Fischer, M. Grandoch (Düsseldorf)

p26 The contribution of the PKA subunit RIα to normal cardiac physiology S. Jamra, A. Ludwig, S. Herrmann (Erlangen), J. S. Schulte (Münster)

p27 Metamizol analgesia after coronary artery bypass surgery achieves plasma concentrations that can severely interfere with the antiplatelet action of aspirin C. Dücker (Göttingen), N. Zimmermann, K. Bartkowski T. Hohlfeld (Düsseldorf)

p28 Transcriptional effects of palmitoleic acid stimulation in primary murine cardiomyocytes and its effects in an isoproterenol mouse model I. R. Betz, S. Brix, N. H. Uhlenhaut, F. Greulich, J. Grune, N. Beyhoff U. Kintscher, A. Foryst-Ludwig (Berlin)

p29 Modelling human heart muscle development in bioengineered heart muscle F. Raad (Göttingen), J. E. Hudson (Göttingen; Brisbane/AU), M. Tiburcy A. Roa (Göttingen), S. Uchida (Frankfurt a. M.) W.-H. Zimmermann (Göttingen)

p30 Deletion of B56α, a regulatory subunit of protein phosphatase 2A, results in prolonged calcium and contraction kinetics D. Glaser, C.-F. Pluteanu, F. U. Müller, P. Boknik, U. Kirchhefer (Münster)

p31 Gender-dependent regulation of protein phosphatase 1 (PP1) isoforms in human heart failure and atrial fibrillation S. Meyer-Roxlau, S. Lämmle (Dresden), S. Neef, S. Sossalla (Regensburg) F. Schöndube (Göttingen), K. Alexiou, S. Weber, A. El-Armouche (Dresden)

p32 Regulation of mitochondrial complex I influences the force-frequency relationship in electrically conditioned engineered human myocardium N. Liaw, L. M. Iyer, M. Tiburcy, T. Meyer, L. C. Zelarayán W.-H. Zimmermann (Göttingen)

p153 Identification of bindings sites of short CREM isoforms to the human genome using Chromatin Immunoprecipitation DNA Sequencing A. Sternberg, M. D. Seidl, S. Hamer, K. Grimm, F. U. Müller (Münster)

6060


Pharmacology – Central nervous system pharmacologyChair H. Kleinert (Mainz)

p33 Analysis of the ligand binding site of the human Mas-related G-protein coupled receptor D by site-directed mutagenesis M. Arbogast, D. M. F. Hanna, S. Müller, N. Sargheini, K. Hoffmann I. von Kügelgen (Bonn)

p34 N2B-patch – an innovative intranasal CNS drug delivery platform J. Flamm, S. Ladel, F. Maigler, C. Hamp, C. Mavoungou K. Schindowski (Biberach a. d. R.)

p35 Changes of consumption of cannabinoids G. Bode, M. Grapp, A. Leha, W. Grellner (Göttingen)

p36 Assessing the transduction profile of the brain-endothelial directed gene vector AAV-BR1 J. Körbelin, M. Kleint, G. Dogbevia, J. Ohnmacht (Lübeck) M. Trepel (Hamburg), M. Schwaninger (Lübeck)

p37 Effects of metabotropic glutamate 5 receptor modulators on the severity of dystonia in the dtsz model s. perl, F. Richter, A. Richter (Leipzig)

p38 Investigation of central nervous system activities of aqueous leaf extract of Olax subscorpioidea Oliv. (Olacaceae) in mice O. Salako, S. Adigun (Mushin-Lagos/NG), K. Salako (Lagos/NG), A. Akindele O. Adeyemi (Mushin-Lagos/NG)

p39 Understanding the role of glial cells in Interleukin-1β induced sickness behaviour S. Sundaram, M. Bernau, H. Müller-Fielitz, M. Schwaninger (Lübeck)

p40 Distribution of NOsGC in porcine brain – evidence for a presynaptic role of NOGC-2 in complex with Lin7a C. Elgert, V. Reimann, S. Behrends (Braunschweig)

6161


Pharmacology – GTP-binding proteins & cyclic nucleotides IChair B. Moepps (Ulm)

p41 The regulation of septins in ciliogenesis and septin functions beyond the diffusion barrier F. Lehmann, K. Østevold, K. Aktories, C. Schwan (Freiburg i. Br.)

p42 RGS3L as potential mediator of muscarinic acetylcholine receptor-induced contractility in the myometrium L. Throm, M. Levay, E. Wollmann, S. Berlit, M. Sütterlin T. Wieland (Mannheim)

p43 Septin remodelling is essential for the formation of microtentacles in detached tumor cells K. Østevold, K. Aktories, C. Schwan (Freiburg i. Br.)

p44 Analyzing platelet function in mice lacking Gαi-proteins I. A. M. Groh (Tübingen), D. Cherpokova (Würzburg), V. Devanathan D. Köhler (Tübingen), P. Rosenberger (Frankfurt a. M.) S. Beer-Hammer (Tübingen), I. Pleines, B. Nieswandt (Würzburg) B. Nürnberg (Tübingen)

p45 Salmonella Typhimurium effector protein SseI inhibits chemotaxis and prolongs survival of host cells by activation of heterotrimeric G-proteins T. Brink (Freiburg i. Br.), V. Leiss (Tübingen), P. Siegert, J. K. Ebner T. Lämmermann (Freiburg i. Br.), M. Hensel (Osnabrück) B. Nürnberg (Tübingen), J. H. C. Orth, K. Aktories (Freiburg i. Br.)

p46 cUMP hydrolysis by PDE3B E. Schneider, J. Ostermeyer, F. Golly (Hannover), S. Dove (Regensburg) V. Kaever, R. Seifert (Hannover)

p47 Inhibition of cyclic GMP export by multidrug resistance protein 4: A new strategy to treat erectile dysfunction? J. Van de Voorde, C. Boydens, B. Pauwels, L. Vanden Daele (Ghent/BE)

p48 Synergistic stabilisation of NOsGC by cinaciguat and non-hydrolysable nucleotides – evidence for sGC activator-induced communication between the heme-binding and catalytic domains A. Sömmer, S. Behrends (Braunschweig)

6262


Pharmacology – ImmunopharmacologyChair M. Kracht (Gießen)

p49 Pathophysiological interactions between miRNAs and nuclear receptors during inflammation N. Kugler, K. Klein, U. M. Zanger (Stuttgart, Tübingen)

p50 Hyaluronan Synthase 3 deficiency leads to reduced leukocyte infiltration and neovessel-formation in a mouse model of hind limb ischemia. R. Schneckmann, T. Driesen, T. Freudenberger, C. Lorenz, C. Heiss M. Kelm (Düsseldorf), S. Hartwig, L. Stefan (Düsseldorf, Munich) J. W. Fischer, M. Grandoch (Düsseldorf)

p51 Hyaluronan-synthase 2 deficiency results in poor cardiac healing and reduced macrophage abundance in the heart after ischemia/reperfusion A. Petz, D. J. Gorski, S. Gorressen, M. Abrams, K. Feldmann, J. Müller S. Hartwig, S. Lehr, M. Grandoch, J. W. Fischer (Düsseldorf)

p52 Identification of potent and selective human TLR2 inhibitors M. Grabowski, M. S. Murgueitio, M. Bermudez, G. Wolber G. Weindl (Berlin)

p54 Differential modulation of inflammatory responses in macrophages by chloroquine C. Lübow, G. Weindl (Berlin)

p55 Single molecule fluorescence in situ hybridisation-based investigations of cytokine-regulated gene expression C. Mayr-Buro, K. Beuerlein, V. Maßmann, S.-S. Weiterer, M. Kracht (Gießen)

p56 The combined phosphoryl-, ubiquitinyl- and acetyl-proteome of cytokine-activated cells a. Weber (Gießen), H. Gu (Danvers, MA/US), H. Müller, M. L. Schmitz M. Kracht (Gießen)

6363


Pharmacology – Membrane transporters IChair M. V. Tzvetkov (Göttingen)

p57 Transcriptional and epigenetic regulation of metabolizing enzymes and transporter proteins in the human intestine by rifampicin and carbamazepine S. Brück, D. Busch (Greifswald), H. Bruckmüller (Kiel) W. Siegmund (Greifswald), I. Cascorbi (Kiel), S. Oswald (Greifswald)

p58 Contribution of MATE1 to the renal secretion of Trimethylamine-N-oxide (TMAO) a. Gessner, J. König, M. Fromm (Erlangen)

p59 Contribution of OCT2-mediated uptake and MATE1-mediated export to renal secretion of trospium B. Deutsch (Erlangen), C. Neumeister, U. Schwantes (Bamberg), M. Fromm J. König (Erlangen)

p60 Development of Solute Carrier (SLC) transporters kidney cell models using hTERT-immortalised Renal Proximal Tubule Epithelial Cells (RPTEC/TERT1) J. Lier (Wesel), C. Zou, R. McDaniel, C. Annesi (Gaithersburg, MD/US)

p61 Expression and regulation of metabolizing enzymes and transporter proteins in intestinal cell lines A. Fritz, S. Brück, P. Erdmann, L. Plantera, J. Müller, S. Oswald (Greifswald)

p62 Cellular uptake of the atypical antipsychotic agent clozapine and its major metabolite desmethylclozapine is independent from hepatic OATP1B membrane transporters a. T. nies, E. Schäffeler, M. Schwab (Stuttgart, Tübingen)

p63 Cloning and functional characterization of primate Ntcps and their interaction with the human and woolly monkey hepatitis B virus S. F. Müller, A. König, B. Döring, D. Glebe, J. Geyer (Gießen)

Pharmacology – Cancer pharmacology & treatment IChair P. Gierschik (Ulm)

p64 Relevance of the last exon of the WWOX gene for cytostatic drug sensitivity T. Moik, K. Bokelmann, J. Brockmöller, M. A. Schirmer (Göttingen)

p65 Chances for reducing rodent carcinogenicity testing G. Bode (Göttingen), J. W. van der Laan (Utrecht/NL)

6464


p66 Lung cell carcinoma and immunohistochemical staining of MUC 1 G. Bode (Göttingen), M. Paulitschke, K. Joehrens (Berlin)

p67 Insights into the mechanism of isoenzyme-specific signal peptide peptidase-mediated translocation of heme oxygenase B. Schäfer, I. Glöckner (Braunschweig), K. Moriishi (Yamanashi/JP) S. Behrends (Braunschweig)

p68 Impact of the green tea polyphenol (-)-epigallocatechin-3-gallate on histone deacetylases in human colon carcinoma HT29 cells T. Pöppelmann, J. Feuls, M. Esselen (Münster)

p69 Loss of MARCKS increases chemoresistance T. Wenzel, T. Büch, A. Aigner, M. Schaefer, H. Kalwa (Leipzig)

Clinical Pharmacology – In vitro systems and disease modelsChair R. Seifert (Hannover)

p70 Development of a cell-based Corin Assay F. Wunder, P. Lambertz, L. Theisen (Wuppertal), C. Garvie, B. MacDonald N. Elowe (Cambridge, MA/US), D. Zubov (Wuppertal) V. Kaushik (Cambridge, MA/US)

p71 Regenerative potential of adipocytes – Potential treatment for hypertrophic scars? K. Hörst (Berlin), L. van den Broek, S. Gibbs (Amsterdam/NL) U. von Fritschen, S. Hedtrich (Berlin)

p72 A universal design of fully synthetic Shark-Human antibody A. Solemanizadeh (Biberach a. d. R.), P. Martineau (Montpellier/FR) K. Schindowski (Biberach a. d. R.)

p73 Comparison between singular gas chromatography mass spectrometry detection (GC/MS) and combined GC/MS plus GC nitrogen-phosphorus detection in general unknown screening of acute clinical toxicological analysis N. Apel, U. Walther (Rostock)

p74 Cytotoxicity monitoring for safety assessments – iPS cardiomyocytes and cancer cells K. Juhasz, S. Stölzle-Feix (Munich), C. T. Bot (Livingston, NJ/US) E. Dragicevic, L. Doerr, M. Beckler, M. George (Munich) R. Haedo (Livingston, NJ/US), N. Fertig (Munich)

6565


p75 Intrinsically increased expression of skin barrier proteins and antimicrobial peptides in filaggrin-deficient skin models is abolished by Th2 cytokines S. Hönzke, M. Schäfer-Korting, S. Hedtrich (Berlin)

p76 Chronic statin exposure increases the lifespan of C. elegans in a DAF-16 (hFOXO3a) dependent manner A. Jahn, G. Fritz, S. Honnen (Düsseldorf)

p77 The role of HCA2 activation for the treatment of pemphigoid diseases M. Wannick, J. Assmann, D. Zillikens, C. Sadik, M. Schwaninger (Lübeck)

p78 Modelling skeletal muscle disorders in engineered 3D cultures T. Rekersbrink, J. Zschüntzsch, W.-H. Zimmermann, J. Schmidt M. Tiburcy (Göttingen)

p79 Cardioprotection against hypoxia/reoxygenation injury in engineered human myocardium E. Levent, C. Noack, L. C. Zelarayán, D. Katschinski, W.-H. Zimmermann, M. Tiburcy (Göttingen)

p80 3D organoid culture – hiPSC-derived kidney organoid as a potential new tool for disease modelling and drug testing K. Sekeres, A. Wagner, C. Hugo, K. Guan (Dresden)

p81 Investigation of selective and non-selective cyclooxygenase-inhibitors on sulfur mustard (SM) induced cell damage s. Wagner, S. Lang, T. Popp, A. Schmidt, K. Kehe, H. Thiermann D. Steinritz (Munich)

Clinical Pharmacology – Research in clinical pharmacologyChair U. Fuhr (Cologne)

p82 Impact of fasted or fed conditions on pharmacokinetic (PK) profile of ibuprofen (IBU) from a fixed dose combination IBU/caffeine (400/100 mg; FDC) in comparison to 400 mg IBU as acid or lysinate – data from 2 single dose, randomised crossover studies in healthy subjects T. Weiser, T. Mück, E. Richter, R. Lange (Frankfurt a. M.)

p83 Determination of the permeation and penetration of flurbiprofen from a locally acting sore throat lozenge and spray into human pharynx tissue using a novel ex-vivo model and a validated analytical method R. Turner, S. R. Wevrett, S. Edmunds (Guildford/GB) M. Brown (Guildford, Hatfield/GB), R. Atkinson (Hull/GB) T. Shea (New Jersey, NJ/US)

6666


p84 Rivaroxaban and macitentan can be administered concomitantly without dose adjustment L. Werntz, A. Huppertz, N. Hohmann, A. D. Meid, K. I. Förster, J. Burhenne D. Czock, J. Weiß, G. Mikus, W. E. Haefeli (Heidelberg)

p85 Lack of mutual pharmacokinetics DDIS for a novel transporter phenotyping cocktail C.-h. Hsin (Cologne), M. Kinzig (Nuremberg-Heroldsberg) E. Schäffeler (Stuttgart, Tübingen), R. Lenssen, M. Taubert, C. Trueck M. Gazzaz, M. Quasdorff (Cologne), M. Schwab (Stuttgart, Tübingen) F. Sörgel (Nuremberg-Heroldsberg), M. Stoffel, U. Fuhr (Cologne)

p86 Tolerability and analgesic efficacy of loxapine in patients with refractory, chemotherapy-induced neuropathic pain S. Schmiedl, D. Peters (Wuppertal, Witten), O. Schmalz A. Mielke (Wuppertal), P. Thürmann (Wuppertal, Witten) A. Schmidtko (Witten, Frankfurt a. M.)

p87 Discontinuation and dose adjustments of Metoprolol after Metoprolol- Paroxetine/Fluoxetine Co-prescriptions in Dutch elderly M. A. Bahar, Y. Wang, J. H.J. Bos, B. Wilffert, E. Hak (Groningen/NL)

Toxicology – Biotransformation and toxicokinetics

p88 Desorption kinetics of organic chemicals from albumin S. Krause, K.-U. Goss (Leipzig)

p89 Structure-dependent activation of the human nuclear receptors AhR and CAR by different polycyclic aromatic hydrocarbons S. Hessel-Pras, T. Szameitpreiks, T. Füllborn (Berlin), A. John A. Seidel (Grosshansdorf), A. Lampen, A. Braeuning (Berlin)

p90 Harmful body care products – an insight into a possible detoxification pathway in humans by AKR1B1 and AKR1B10 D. Appel, J. Hintzpeter, H.-J. Martin, e. Maser (Kiel)

p91 Reverse dosimetry approach for potential endocrine disruptors: simple kinetic modelling versus PBTK e. fabian, A. Ochs, C. Haase, C. Gomes, B. Birk, T. Ramirez-Hernandez R. Zbranek, B. van Ravenzwaay, R. Landsiedel (Ludwigshafen a. R.)

p92 Characterization, modification and applicability of an in vitro placental transfer assay for screening purposes C. Gomes, C. W. van Dongen, B. Birk, E. Fabian, J. Doersam, B. van Ravenzwaay, R. Landsiedel (Ludwigshafen a. R.)

6767


Toxicology – Organ toxicology

p93 Quantification of proximal tubular injury biomarkers via novel mass spectrometry-based immunoassays in tobramycin-treated canine urine W. Naboulsi, H. S. Hammer (Reutlingen), M. Sonee (Spring House, PA/US) Y. Chen (San Diego, CA/US), S. Bryant, C. Johnson (Spring House, PA/US) L. Nguyen, B. Scott (San Diego, CA/US), T. O. Joos (Reutlingen) J. E. McDuffie (San Diego, CA/US), O. Poetz (Reutlingen)

p94 Suitability of human and rat small bowel preparations as tissue in an organophosphate poisoning model K. Marquart, O. Prokopchuk, F. Worek, H. Thiermann, M. Martignoni T. Wille (Munich)

p95 Molecular changes in mice following 3 weeks of inhalation exposure to e-vapor aerosols in comparison with cigarette smoke U. Kogel, F. Martin, B. Titz, N. V. Ivanov, E. Guedj, A. Elamin P. Vanscheeuwijck, M. C. Peitsch (Neuchatel/CH) K. M. Lee (Richmond, VA/US), J. Hoeng (Neuchatel/CH) S. J. Harbo (West Jefferson, OH/US), W. P. Gardner, M. J. Oldham J. Zhang W. J. McKinney (Richmond, VA/US)

p96 Baseline variability of the gut microbial community and related metabolic changes in plasma and feces C. Behr (Ludwigshafen a. R.), H. J. Cameron (Research Triangle Park NC/US) V. Strauss (Ludwigshafen a. R.), T. Walk (Berlin) B. van Ravenzwaay (Ludwigshafen a. R.)

p97 A promising tool for investigation of the mode of action of nephrotoxicants: metabolome analysis in vitro in NRK-52e cells B. Birk, S. Sperber, H.-A. Huener, A. Verlohner (Ludwigshafen a. R.) T. Walk, V. Haake, M. Spitzer (Berlin), T. Ramirez, H. Kamp B. van Ravenzwaay (Ludwigshafen a. R.)

p98 Chronic AngII-induced hypertension leads to impaired renal function and initiation of epithelial to mesenchymal transition in rat kidneys C. Hartmann, N. Schupp (Düsseldorf)

p99 Tight junction proteins and barrier integrity of the Caco-2 intestinal model are affected by the marine biotoxin okadaic acid J. Dietrich, I. Grass, A. Braeuning, A. Lampen, S. Hessel-Pras (Berlin)

p100 Pyrrolizidine alkaloid-induced hepatotoxicity in the human hepatoma cell line HepaRG – single versus repeated exposure J. Waizenegger, A. Braeuning, A. Lampen, S. Hessel-Pras (Berlin)

6868


p101 Pyrrolzidine alkaloids – metabolism-dependent molecular effects in human endothelial cells J. Ebmeyer, M. Lorenz, A. Braeuning, A. Lampen, S. Hessel-Pras (Berlin)

p102 Insights into the production of neurotoxin associated proteins from C. botulinum strain Beluga A. Przykopanski (Hannover), M. Krüger (Berlin), J. Lübke, A. Kroh (Hannover) R. Jin (Irvine, CA/US), B. Dorner (Berlin), A. Rummel (Hannover)

p103 Investigations of the neurotoxic effects of engineered nanoparticles in the mouse brain – the N3RvousSystem project A. Sofranko, T. Wahle (Düsseldorf) H. J. Heusinkveld (Düsseldorf; Bilthoven, Utrecht/NL) D. Breitenstein (Münster), B. Stahlmecke, B. Hellack (Duisburg), C. Albrecht R. P. F. Schins (Düsseldorf)

p104 Practice-driven approach to harmonize reproductive and thyroid hormones measurements in the evaluation of pesticides and biocides O. Kucheryavenko, G. Lurman, A. Lehmann (Berlin), J. Braz (Brasilia/BR) L. Niemann, V. Ritz (Berlin), A. Terron (Parma/IT), R. Solecki (Berlin)

p105 Mitochondrial damage induced by methylene blue and toluidine blue in A549 and L929 cells E. Bekka, C. Hopfer, F. Eyer, H. Mückter, T. Gudermann (Munich)

Toxicology – Methods in toxicology

p106 Skin sensitization quantitative risk assessment for occupational exposure of hairdressers to hair dye ingredients C. Goebel (Darmstadt), T. Diepgen (Heidelberg), B. Blömeke (Trier) A. Gaspari (Baltimore, MD/US), J. McFadden (London/GB) A. Schnuch (Göttingen), A. Fuchs (Darmstadt), K. Schlotmann (Düsseldorf) M. Krasteva (Clichy/FR), I. Kimber (Manchster/GB)

p107 Impact of pesticide residues in feed on animal health A. Schmitt, L. Niemann (Berlin)

p108 Measuring microbial pattern changes in the murine gut by high-resolution flow cytometry A. Weker (Düsseldorf), F. Heinrich, H.-D. Chang (Berlin), c. esser (Düsseldorf)

6969


p109 An in vitro coculture system composed of THP-1 cells and 3D reconstructed human epidermis to assess activation of dendritic cells by sensitizing chemicals M. T. Schellenberger, U. Bock, J. Hennen (Trier), F. Gröber-Becker H. Walles (Würzburg), B. Blömeke (Trier)

p110 An example about the conceptual work in evaluation and classification of chemical substances – a guideline for the evaluation of the carcinogenicity looking at the human relevance of tumors in animal experiments S. Michaelsen, B. Laube, P. Kreis, V. Meischner, G. Schriever-Schwemmer N. Volz, K. Ziegler-Skylakakis, H. Greim, A. Hartwig (Karlsruhe)

p111 GHS additivity formula – Can it predict the acute systemic toxicity of agrochemical formulations that contain acutely toxic ingredients? A. van Cott, C. Hastings (Research Triangle Park, NC/US), R. Landsiedel S. Kolle, S. Stinchcombe (Ludwigshafen a. R.)

Toxicology – Genotoxicity/carcinogenesis

p112 Bladder cancer in crack testers applying azo dye-based sprays to metal bodies – report from recent experience

T. Kadhum, H. Niedner (Dortmund), C. Lukas, H.-M. Prager (Castrop-Rauxel) S. Kopps, S. Selinski, H. M. Bolt, K. Golka (Dortmund)

p113 Human nucleotide excision repair pathway counteracts toxicity of abasic sites N. Kitsera, M. Rodríguez (Mainz), C. Seebode, J. Lehmann S. Emmert (Rostock), A. Khobta (Mainz)

p114 Overexpression of different Rac1 forms alters the DNA damage response in mouse embryonic fibroblasts after treatment with Topoisomerase II poisons R. Kitzinger, G. Fritz, C. Henninger (Düsseldorf)

p115 Development of a high-throughput screening for oxidative DNA damage in human cells M. Mack, A. Bürkle (Konstanz)

p116 AKT2 suppresses pro-survival autophagy triggered by DNA double-strand breaks in colorectal cancer cells N. Seiwert, C. Neitzel (Gießen, Mainz), S. Stroh (Mainz) T. Frisan (Stockholm/SE), M. Audebert (Toulouse/FR) M. Toulany (Tübingen), B. Kaina (Mainz), J. Fahrer (Gießen, Mainz)

7070


p117 Evaluation of toxicity, cytotoxicity and genotoxity of organotheluran RF07 in meristematic cells of Allium cepa L. O. A. d. Carvalho Maia, S. B. Cunha Fontele, D. Cavalcante Braz A. M. Viana Nunes (Teresina/BR) R. L. Oliveira Rodrigues Cunha (São Paulo/BR), J. M. d. Castro e Sousa A. A. d. Carvalho Melo Cavalcante, P. M. d. Almeida (Teresina/BR)

p118 Impact of perfluoroalkylated substances (PFAS) on the phospho-proteome in HepaRG cells A.-C. Behr, T. Buhrke (Berlin), M. F. Templin (Reutlingen), A. Braeuning A. Lampen (Berlin)

p119 The BALB/c 3T3 cell transformation assay – a helpful tool for the development of new cancer therapeutics R. Thierbach, D. Hoelzer (Jena)

Toxicology – Toxicology of nanomaterials

p120 Multimodular fluidic in vitro platform for nanosafety screening Y. Kohl, T. Knoll, M. Hesler (Sulzbach), A. Nelson (Leeds/GB)

p121 Approaches on MWCNT diameters and its relation to tumor development D. Schwotzer (Hannover), A. Meyer-Plath (Berlin), S. Rittinghausen O. Creutzenberg (Hannover), A. Leonhardt (Dresden) D. Schaudien (Hannover)

p122 Toxicological assessment of magnesium oxide nanoparticles on human intestinal cells A. Mittag, T. Schneider, M. Glei (Jena)

p123 Comparative proteomic analysis of effects in rat testis induces by 28-days subacute oral nanosilver treatment S. Juling, A. Oberemm, J. Bornemann, C. Meckert, J. Potkura, A. Braeuning A. Lampen (Berlin)

p124 Caracterization and cytotoxic assessment of poly (methyl methacrylate) nanoparticles containing alpha-terpineol F. Alves Batista, S. B. Cunha Fontele, M. Gomes de Farias J. M. d. Castro e Sousa, A. Nogueira Mendes J. C. Ramos Gonçalves (Teresina/BR)

7171


Toxicology – Toxins

p125 The peptide antibiotic bacitracin protects mammalian cells from intoxication with bacterial AB-toxins L. Schnell, I. Felix, M. Sadi, H. Barth (Ulm)

p126 Pertussis toxin requires host cell chaperones for its uptake into mammalian cells K. Ernst, A.-K. Mittler, N. Eberhardt, M. Vollmer, J. Wirsching, A. Anastasia H. Barth (Ulm)

p127 Development of a cellular transport system for the tumor metastasis suppressor protein Nm23H1/NDPK-A I. Felix (Ulm), T. Wieland (Mannheim), H. Barth (Ulm)

p128 Exploitation of non-toxic diphtheria toxin for molecular Trojan horse development s. carle, M. Fellermann, H. Barth (Ulm)

p129 Comparison of silibinin-BS, silibinin-EtOH and penicillin G treatment after α-amanitin poisoning in vitro T. Popp, F. Balszuweit, A. Schmidt, F. Eyer, H. Thiermann D. Steinritz (Munich)

p130 Bacitracin protects human cells from Clostridium difficile toxins TcdA and TcdB Z. Zhu, L. Schnell (Ulm), C. Schwan, K. Aktories (Freiburg i. Br.) H. Barth (Ulm)

p131 Enhanced uptake of Clostridium sordellii Lethal Toxin into murine fibroblasts upon stress induction D. Schöttelndreier, I. Schelle, R. Lindner, H. Genth (Hannover)

p132 Role of integrin α5β1 in binding of C3 exoenzyme N. Schecker, S. Hagemann, I. Just, A. Rohrbeck (Hannover)

p133 The translocation rate of Clostridium difficile TcdB is decisive for the induction of cytopathic or cytotoxic effects in host cells L.-A. Beer, H. Tatge, R. Gerhard (Hannover)

p134 Development of high-affinity monoclonal antibodies for the detection of non-toxic complex proteins of botulinum neurotoxin M. Krüger, D. Stern (Berlin), N. Krez, A. M. Kruel, J. Lübke (Hannover) M. Dorner (Berlin), A. Rummel (Hannover), B. Dorner (Berlin)

7272


p136 Mucus-mediated protection of colonic HT29 cells from C. difficile Toxin B M. Wilhelm, G. Grassl, H. Genth (Hannover)

p137 Asthma and COPD therapeutics for supportive treatment in nerve agent poisoning – a study in rat PCLS J. Herbert, F. Worek, H. Thiermann, T. Wille (Munich)

p137a Two novel clostridial glucosylating-like toxins expressed in a Yersinia spp S. Ost, B. Schorch, P. Papatheodorou, C. Schwan, Y. Belyi K. Aktories (Freiburg i. Br.)

General – EducationChair O. Zolk (Ulm)

p138 PubPharm – the search engine for pharmacology, toxicology & pharmacy- specific literature A. Krüger, K. Keßler, J. Wawrzinek, S. Wulle, W.-T. Balke K. Stump (Braunschweig)

p139 Finally confident – self-appraisal of pharmacological deficits by medical students and alumni B. Frings, W. Johannsen, S. Herzig, J. Matthes (Cologne)

p140 Recognition and training of specialists in clinical pharmacology in Europe: A pilot survey of the UEMS section of pharmacology T. Griesbacher (Graz/AT; Bruxelles/BE)

p141 Ten years Master Program in Toxicology at the University of Kaiserslautern S. Stegmüller, D. Schrenk (Kaiserslautern)

7373

POSTER SESSION II • WEDNESDAY, 28 FEBRUARY

13:00–14:00 Poster session IIPosters should be mounted by Monday or Tuesday morning and be removed on Wednesday by 17:00 at the latest. The presenting authors must be present during the poster session II. Please note the hints for poster presentations on page 12.

Pharmacology – Cancer pharmacology & treatment IIChair U. Fuhr (Cologne)

p142 Metronomic doxorubicin treatment with a new nanogel-based drug delivery system D. Hölzer, M. N. Leiske, M. Hartlieb, T. Bus, D. Pretzel, S. Hoeppener K. Kempe, R. Thierbach, U. S. Schubert (Jena)

p143 microRNA expression and clinical outcome of chronic myelogenous leukemia T. Klümper, H. Bruckmüller, M. Kähler, T. Diewock, S. Haenisch, C. Pott M. Kneba, O. Bruhn, I. Cascorbi (Kiel)

p144 Formation of the novel MKL1-Filamin A complex upon loss of the tumor suppressor Deleted in Liver Cancer 1 (DLC1) promotes hepatocellular carcinoma growth M. A. Meier, K. Woerther, C. Hermanns, T. Gudermann, S. Muehlich (Munich)

p145 Extracellular vesicles (exosomes) as new tissue specific delivery system for therapeutic small RNAs P. Zhupanyn, A. Ewe (Leipzig), A. Malek (Saint-Petersburg/RU) A. Aigner (Leipzig)

p146 HER3 activation in gastric cancer cells leads to increased cellular adhesion and reduced invasiveness T. Büch, M. Rein, H. Kalwa, R. Jenke, F. Lordick, A. Aigner (Leipzig)

p147 Sensitization of colorectal cancer cells to topoisomerase I Inhibitors via pharmacological inhibition of IAPs C. Steigerwald, B. Rasenberger, B. Kaina, M. Christmann, M. Tomicic (Mainz)

p148 A promising building block in the chemotherapy of colorectal cancer: The first-in-class mitochondrial disruptor CPI-613 C. Neitzel (Gießen, Mainz), S. Stroh, G. Nagel (Mainz) J. Fahrer (Gießen, Mainz)

7474


Pharmacology – Cardiovascular pharmacology & treatment IIIChair K. Lorenz (Dortmund)

p149 The effect of anesthetic on hemodynamics measurements in a rat model of monocrotaline-induced pulmonary arterial hypertension

J. Huang, H. Wang, L. A. A. Neves, O. Tiniakova, P. B. Senese M. R. Gralinski (Chicago, IL/US), F. J. Hock (Dieburg)

p150 Histamine increases contractility in isolated cardiomyocytes of mice overex-pressing the H2-receptor

J. Fröba, U. Gergs, J. Neumann (Halle a. d. S)

p151 Effects of nebivolol on myofilament calcium sensitivity in muscle strips of mouse and human hypertrophic cardiomyopathy heart tissue

F. Friedrich, S. Stücker, N. Kresin, L. Carrier (Hamburg)

p152 Rat atrial engineered heart tissue – a new tool to study atrial biology in vitro J. Krause, A. Löser, M. Lemoine, T. Christ, S. Blankenberg, T. Zeller T. Eschenhagen, J. Stenzig (Hamburg)

p154 Cardiovascular effects of cannabidiol in normotensive and spontaneously hypertensive rats B. Malinowska, R. Kossakowski, E. Grzeda, J. Weresa (Bialystok/PL) E. Schlicker (Bonn)

p155 Modulation of Crem isoforms represent a time dependent regulatory system for the transcriptional gene response after beta adrenergic stimulation in the heart

M. D. Seidl, K. Grimm, S. Hamer, B. Fels, D. S. Kranick, A. Sternberg J. S. Schulte, F. U. Müller (Münster)

p156 SB202190 inhibits endothelial cell apoptosis via induction of autophagy and heme oxygenase-1 M. Schwartz, S. Boeckmann, P. Borchert, B. Hinz (Rostock)

7575


Pharmacology – Cardiovascular pharmacology & treatment IVChair J. Matthes (Cologne)

p157 Phosphorylation of β-catenin by β2-adrenoceptor activation in endothelial cells S. Jansen, T. Wieland (Mannheim)

p158 GSH and H2o2 redox assessment in human stem cell derived cardiomyocytes I. Eckhardt, P. L. Soong (Göttingen), V. Belousov (Göttingen; Moscow/RU) W.-H. Zimmermann (Göttingen)

p159 Effect of the oxidant tert-butylhydrochinone (tBHQ) on functionality of WRN-deficient endothelial cells (HUVEC) K. Laarmann (Düsseldorf), J. M. Kreß, B. Kaina (Mainz), G. Fritz (Düsseldorf)

p160 In vivo and in vitro differentiation of cardiac myocytes differentially affects chromatin organization and DNA methylation R. Gilsbach, S. Nothjunge, V. Ngo (Freiburg i. Br.), S. A. Doppler (Munich) M. Hesse, B. Fleischmann (Bonn), M. Krane (Munich) L. Hein (Freiburg i. Br.)

p161 Chromatin accessibility in healthy and diseased cardiac myocyte nuclei M. barg, R. Gilsbach, T. Kehl, L. Hein (Freiburg i. Br.)

p162 Influence of chronic AT1 receptor blockade on gastric barrier function in mice L. Nickel, E. Rawish, A. Sünderhauf, C. Sina, W. Raasch (Lübeck)

p163 Impact of trimethylamine N-oxide (TMAO) on antiplatelet effect of a loading dose of clopidogrel 600 mg C. Stratz (Bad Krozingen), A. Gessner (Erlangen), J. Hromek T. G. Nührenberg, L. Hille, W. Hochholzer (Bad Krozingen) M. Fromm (Erlangen), D. Trenk (Bad Krozingen)

p164 Impact of clopidogrel therapy on incidence of early hypo-attenuated leaflet thickening after transcatheter aortic valve replacement T. G. Nührenberg, J. Hromek, A. Kille, W. Hochholzer, P. Ruile F.-J. Neumann D. Trenk, C. Stratz (Bad Krozingen)

p165 Inducible cAMP early repressor (ICER) protects from electrophysiological remodelling induced by short-term β-adrenergic stress J. S. Schulte, J. Obergassel, M. D. Seidl, A. Sternberg, K. Grimm F. U. Müller (Münster)

7676


Pharmacology – Cardiovascular pharmacology & treatment VChair S. Engelhardt (Munich)

p166 Calcitriol enhances contractile function of engineered human myocardium S. F. Schlick, M. Tiburcy (Göttingen), J. Garbern (Cambridge, MA/US) S. Zeidler, E. Wingender (Göttingen), R. Lee (Cambridge, MA/US) W.-H. Zimmermann (Göttingen)

p167 Insulin augments calcium transients and increases spontaneous calcium release events in rat atrial myocytes B. Kollmeier, C. Dienemann, E. Knefeli, J. Kockskämper (Marburg)

p168 Defining the role of Wnt-mediated extracellular vesicle signalling during cardiac remodelling T. Weber, E. Schoger, C. Noack, J. C. Gross, W. Möbius L. C. Zelarayán (Göttingen)

p169 The characterization of cardiac molecular defects in an in vitro disease model of Vici syndrome and identification of potential therapeutic target e. a. alfar (Dresden), J. Qi (Göttingen), J. Gommlich (Dresden) M. Gautel (London/GB), K. Guan (Dresden)

p170 Exosomes in Aortic Valve Disease – Identification and potential function D. Goody, P. R. Goody, G. Nickenig, N. Werner, F. Jansen, A. Pfeifer (Bonn)

p171 Transcriptome and chromatin changes in rat cardiomyocytes upon differentiation and cytokine stimulation L. Jurida, S. Werner, M. Creutzburg, M. Bartkuhn (Gießen) A. Nist (Marburg), S. Rohrbach, M. Kracht (Gießen)

p172 Enhanced phospholamban activity suppresses cardiomyocyte calcium cycling in the remote myocardium early after myocardial infarction F. Funk, A. Kronenbitter (Düsseldorf), D. Glaser, P. Boknik (Münster) J. P. Schmitt (Düsseldorf)

p173 Cardiomyocyte NO-sensitive guanylate cyclase limits the extent of ischemia- and reperfusion-induced cardiac injury S. Frankenreiter, A. Kuret (Tübingen), D. Groneberg (Würzburg) P. Ruth (Tübingen), A. Friebe (Würzburg), R. Lukowski (Tübingen)

p174 Lipopolysaccharide-induced renal prostaglandin E2 formation preserves renal function in endotoxemia-related acute kidney injury in mice M. Meurer (Erlangen), F. Schweda (Regensburg), K. Höcherl (Erlangen)

7777


Pharmacology – EnzymesChair A. Aigner (Leipzig)

p175 ROCK inhibition impacts myofibroblastic processes G. Leao Santos, S. Hartmann, K. Xhaxho, S. F. Schlick (Göttingen) A. Ridley (London/GB), M. Tiburcy, S. Lutz (Göttingen)

p176 Direct assessment of the interaction of nucleoside diphosphate kinases with heterotrimeric G-proteins S. K. Lomada (Mannheim), A. Kannt (Frankfurt a. M.) P. Attwood (Crawley/AU), T. Wieland (Mannheim)

p177 Functional reconstitution of the B-cell receptor signalling in COS-7 cells M. Wist, Y. Zhou, A. Schade, J. Haas, P. Gierschik, C. Walliser (Ulm)

p178 The combination of dichloroacetate and a hyaluronan synthesis inhibitors synergistically induces apoptosis in esophageal squamous carcinoma cells C. Reichert, S. Twarock, O. Reiners, J. W. Fischer (Düsseldorf)

p179 Exploring the putative self-binding property of the human farnesyltransferase alpha-subunit A. Hagemann (Witten, Essen), G. Müller, I. Manthey (Essen) H. S. Bachmann (Witten)

p180 CRISPR/Cas9 mediated genome editing of Cytochrome P450 Reductase (POR) in HepaRG Cells T. Petrikat, K. Klein, U. M. Zanger (Stuttgart)

p181 Detoxification of reactive carbonyl compounds by carbonyl reductase “sniffer” in the aquatic model organisms Daphnia magna and Daphnia pulex J. S. Strehse, N. Protopapas, M. Kisiela, B. Ebert, E. Maser (Kiel)

p182 CRTC1-deficient mice show a reduced induction of fibrosis K. Morhenn (Hamburg), K. Saar, N. Hübner (Berlin), E. Oetjen (Hamburg)

7878


Pharmacology – G-protein coupled receptors IIChair T. Eschenhagen (Hamburg)

p183 Carboxyl-terminal multisite phosphorylation regulates µ-opioid receptor desensitization and tolerance A. Kliewer (Jena), J. Williams (Portland, OR/US), A. Bailey (London/GB) S. Schulz (Jena)

p184 The complex role of mu-opioid receptor phosphorylation in the recruitment of G protein-receptor kinases and β-arrestins e. Miess (Jena), A. Gondin (Parkville/AU), R. Steinborn (Jena), N. Mösslein Y. Yang, M. Göldner, J. Ruland (Marburg), M. Christie (Sydney/AU) M. Bünemann, C. Krasel (Marburg), M. Halls (Parkville/AU), S. Schulz (Jena) M. Canals (Parkville/AU)

p185 Analysis of neurotransmitter-induced calcium mobilization in astrocytes J. Ostermeyer, M. Stangel, R. Seifert, E. Schneider (Hannover)

p186 Role of Galpha C-terminal helix for binding affinity to muscarinic receptors V. Jelinek, M. Bünemann (Marburg)

p187 Voltage dependence of the thromboxane receptor M. Kurz, A.-L. Krett, M. Bünemann (Marburg)

p188 Mutation of lysines to arginines in the N-terminus of arrestin lowers the affinity of arrestin to GPCRs by attenuating the release of the arrestin C-terminus N. Mösslein (Marburg), D. Zindel (Marburg; Montpellier/FR) J. K. S. Tiemann (Leipzig), M. E. Sommer (Berlin), J.-P. Pin L. Prézeau (Montpellier/FR), P. W. Hildebrand (Leipzig), M. Bünemann C. Krasel (Marburg)

p189 Agonist specific voltage sensitivity at the mu-opioid receptor S. Kirchhofer, J. Ruland, M. Bünemann (Marburg)

p190 Using GIRK channels to elucidate the in vitro pharmacology of somatostatin analogues with the help of a fluorescence based membrane potential assay P. Dasgupta, T. Günther, J. Modrow, S. Schulz (Jena)

7979


Pharmacology – GTP-binding proteins & cyclic nucleotides IIChair E. Schneider (Hannover)

p191 Does cyclic GMP affect cell cycle regulation? K. Broekmans, D. Koesling, E. Mergia (Bochum)

p192 Identification of a new binding pattern for cCMP and cUMP in the AKAP9 splice variant Yotiao S. Wolter, T. Hagedorn, T. Koenig (Hannover) C. W. Dessauer (Houston, TX/US), R. Seifert (Hannover)

p193 Treatment with esomeprazole weakens the development of splenomegaly associated anemia in global IRAG-deficient mice M. Majer, A. Schramm, J. Schloßmann (Regensburg)

p194 Mechanisms of cystein-rich protein 4 dependent pain processing L. Kennel, J. Petersen, T. Groß, C. Flauaus (Frankfurt a. M.) O. Drees (Witten), H. Schmidt, P. Ruth, R. Lukowski (Tübingen) A. Schmidtko (Frankfurt a. M.)

p195 Slow cAMP diffusion in intact cells allows cAMP compartmentation in nanodomains by local PDE activity A. Bock, P. Annibale (Berlin, Würzburg), A. Hannawacker (Würzburg) M. J. Lohse (Berlin, Würzburg)

p196 Gαi–specific roles in lung function V. leiss, A. Nowacki, S. Ammon-Treiber (Tübingen) J. Bridges (Cincinnati, OH/US), L. Quintanilla-Martinez de Fend H. Wolburg (Tübingen), J. Whitsett (Cincinnati, OH/US) M. Schwab (Tübingen, Stuttgart), S. Beer-Hammer, B. Nürnberg (Tübingen)

p197 Homo- and heterodimerization of the GIP receptor S. Al-Sabah (Kuwait/KW), M. Bünemann, C. Krasel (Marburg)

p198 Directed evolution of human parathyroid hormone 1 receptor for structural and functional studies C. Klenk, J. Ehrenmann, J. Schöppe (Zurich/CH), L. Kummer (Schlieren/CH) A. Plückthun (Zurich/CH)

8080


Pharmacology – Ion channelsChair N. Voigt (Göttingen)

p199 Functional relevance of a point mutation in an autism risk gene coding for the calcium channel subunit Cavβ1b P. Despang, A. Breitenkamp, S. Salamon, M. Brill, S. Herzig J. Matthes (Cologne)

p200 Loss of sodium-activated potassium channel Slack and FMRP differentially affect social behavior in mice A. E. Bausch, R. Dieter, P. Zerfass, Y. Nann, P. Ruth, R. Lukowski (Tübingen)

p201 The sodium-activated potassium channel Slack protects neurons against glutamate receptor mediated excitotoxicity R. Dieter, A. E. Bausch, N. Frank, K. Wild, P. Ruth, R. Lukowski (Tübingen)

p202 Analysis of P2X7R localization in the CNS and consequences of its overexpression using a BAC transgenic mouse model J. Zhang (Munich, Göttingen), K. Kaczmarek-Hájek (Göttingen) R. Stocklauser, A. Grosche (Munich), B. Rissiek (Hamburg), S. Sirko (Munich) V. Eulenburg (Erlangen-Nuremberg), A. Nicke (Munich)

p203 Automated Patch Clamp in safety pharmacology – combining flexibility with high throughput S. Stölzle-Feix, C. Haarmann, T. A. Goetze, M. Rapedius, N. Brinkwirth I. Rinke, K. Juhasz, G. Rascher-Eggstein, E. Dragicevic, A. Brüggemann M. George, N. Fertig (Munich)

p204 Up-regulated DPP10 might promote arrhythmias in heart failure F. Belau (Dresden), K. Metzner (Frankfurt a. M.), P. Jörk, A. El-Armouche K. Guan, S. Kämmerer (Dresden)

p205 Dextromethorphan – A suitable candidate for treatment of type 2 diabetes mellitus? A. Gresch, M. Düfer (Münster)

8181


Pharmacology – Membrane transporters IIChair H. E. Meyer zu Schwabedissen (Basel/CH)

p206 Expression of transporter proteins of the ABC, SLC and SLCO family in glioblastoma stem-like cells S. Bien-Möller, A. Arlt, S. Kaiser, A. Grober, G. Jedlitschky, M. Grube S. Oswald, S. Marx, B. H. Rauch, H. Schroeder (Greifswald)

p207 Functional variants of OCTN transporter genes are associated with total and LDL cholesterol in a body mass-dependent manner P. Meisel, S. Pagels, M. Nauck, H. Völzke, B. H. Rauch, T. Kocher, M. Grube G. Jedlitschky (Greifswald)

p208 Is there an OCT1-mediated transport without aspartate474? M. J. Meyer, M. Bolesta, S. K. Kakkar, T. Seitz, J. Brockmöller M. V. Tzvetkov (Göttingen)

p209 Application of Förster resonance energy transfer (FRET) for the functional characterization of OATP2B1 P. Hagen, G. Jedlitschky, M. Grube (Greifswald)

p210 Global proteomic analysis of transporter proteins in the human small intestine and established intestinal cell lines J. Müller, E. Hammer, M. Gesell Salazar, A. Fritz, L. I. Partecke C.-D. Heidecke U. Völker, S. Oswald (Greifswald)

p211 Inhibition of human OCT1, OCT2, MATE1, OAT1 and NTCP mediated uptake by pesticides A. Kühne, S. Flörl, R. Halpape, Y. Hagos (Göttingen)

p212 The UDP-glucose ceramide glucosyltransferase (UGCG) impacts cell energy metabolism in breast cancer cells M.-S. Wegner (Frankfurt a. M.)

Clinical Pharmacology – Pharmacogenomics & personalised therapyChair K. S. Just (Bonn)

p213 Modelling and simulation of CYP2D6 PM and CYP3A4/5 PM and their effects on population pharmacokinetics of tamoxifen and its main metabolites J. P. Ximenez (Ribeirao Preto/BR), S. D’Agate (London/GB) M. Locci de Oliveira, M. P. Marques Pereira J. Moreira Andrade (Ribeirao Preto/BR), G. Suarez-Kurtz (Rio de Janeiro/BR) O. Della Pasqua (London/GB), V. L. Lanchote (Ribeirao Preto/BR)

8282


p214 The BCL2 -938C>A promoter polymorphism is associated with risk for and time to aseptic loosening of total hip arthroplasty P. Stelmach, C. Wedemeyer (Essen), T. Gehrke (Hamburg), S. Klenke M. Jäger, M. D. Kauther (Essen), H. S. Bachmann (Witten)

p215 Mimicking metabolism in the brain – analysis of cytochrome P450 mediated drug metabolism in iPS-derived cortical organoids by highly sensitive LC – MS techniques N. Beyer, M. Vogel, C. Scholl, J. C. Stingl (Bonn)

p216 Heritability of the variation of human CYP3A activity as assessed by various biomarkers J. Matthaei (Göttingen, Kassel), R. Kerb (Stuttgart) M. V. Tzvetkov (Göttingen), U. Hofmann (Stuttgart) M. Schwab (Stuttgart, Tübingen), J. Brockmöller (Göttingen)

p217 The impact of CYP3A5*3 and CYP3A4*22 polymorphisms on Tacrolimus pharmacokinetics in a Caucasian kidney transplant cohort. E. Abdel-Kahaar (Ulm; Qena/EG; Stuttgart), S. Winter (Stuttgart) E. Schäffeler (Tübingen, Stuttgart), C. Olbricht, M. Shipkova (Stuttgart) M. Schwab (Stuttgart, Tübingen), E. Wieland (Stuttgart)

p218 NOD2 mutations and clinical outcome are not associated in Crohn’s disease treated with helminth ova (Trichuris suis) S. Jaeger, S. Winter, E. Schäffeler, M. Schwab, J. Wehkamp (Stuttgart)

p219 Changes of pharmacotherapy after obesity surgery A. B. Hansen, J. W. Mall, s. engeli (Hannover)

Clinical Pharmacology – Pharmacokinetics and PK-PD modellingChair S. M. Bode-Böger (Magdeburg)

p220 The unbound fraction of amiodarone is an important parameter for modelling the in vivo dose in humans by in vitro-in vivo extrapolation (IVIVE) E. Algharably (Berlin; Cairo/EG), R. Kreutz, U. Gundert-Remy (Berlin)

p221 Influence of fast and slow metabolizer status on the pharmacokinetics of isoniazid in lactating women and breast-fed infants – a physiologically-based pharmacokinetic (PBPK) modelling approach to estimate drug exposure via breast milk in infants E. D. G. Garessus, H. Mielke, U. Gundert-Remy (Berlin)

8383


p222 Two sensitive methods for determination of D-lactate and glycolate in plasma with liquid chromatography and tandem mass spectrometry (LC/MS/MS) R. Oertel, T. Friedrichson, S. Weber, A. El-Armouche (Dresden)

p223 Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia M. Locci de Oliveira, G. Henrique Balthazar Nardotto, L. Francisco Pippa A. Rocha, B. Pinto simões, V. L. Lanchote (Ribeirão Preto/BR)

p224 Mevalonic acid as a biomarker of Fluvastatin in patients with rheumatoid Arthritis J. Caris, A. Rocha, R. Cestari, M. P. Pereira, R. Oliveira V. L. Lanchote (Ribeirão Preto/BR)

p225 Mevalonic acid as a biomarker of Atorvastatin in patients with systemic Lupus Erythematosus R. Cestari, A. Rocha, J. Caris, M. P. Pereira, R. Oliveira V. L. Lanchote (Ribeirão Preto/BR)

p226 Therapeutic drug monitoring of meropenem in intensive care patients: Are dried blood spots a viable alternative to plasma samples? D. Monastyrski, J. Martens-Lobenhoffer, U. Tröger S. M. Bode-Böger (Magdeburg)

p227 Doping in equestrian sports – Meta-analysis to validate international residue limits for the methylxanthines caffeine and theophylline R. Hertzsch, A. Richter (Leipzig)

Toxicology – In silico methods in toxicology

p228 In silico genotoxicity and carcinogenicity prediction for food-relevant secondary plant metabolites J. Glück, T. Buhrke, F. Frenzel, A. Braeuning, A. Lampen (Berlin)

p229 In depth analysis of selected cosmetic ingredients from the SkinAB Database S. Schmeinck, A. Bitsch, H. Genth (Hannover)

p230 QSAR Predictions of Skin Sensitization by Open-Source Tools for 48 selected sensitizing and non-sensitizing active substances in pesticides C. Braeuning, A. Braeuning, H. Mielke, A. Holzwarth, M. peiser (Berlin)

p231 Identifying research areas in need for developing 3R measure B. Bert, B. Grune, G. Schönfelder (Berlin)

8484


Toxicology – In vitro methods in toxicology

p233 The CULTEX® Radial Flow System (RFS) as in vitro screening approach to analyze the acute toxicity of inhalable substances A. Tsoutsoulopoulos, K. Gohlsch (Munich), N. Möhle (Hannover) A. Breit, H. Mückter, T. Gudermann (Munich), O. Krischenowski (Hannover) S. Hoffmann (Paderborn), H. Thiermann (Munich) M. Aufderheide (Hannover), D. Steinritz (Munich)

p234 In vitro toxicity testing – automation of cell-based assays L. Schober, M. Walter, A. Traube (Stuttgart)

p235 Chemotaxis and cytotoxicity of metal oxides G. Westphal, N. Rosenkranz, C. Monsé, M. Kirchner (Bochum), K. Loza A. Rostek, M. Epple (Essen), T. Brüning, J. Bünger (Bochum)

p236 Influence of doxorubicin on differentiation of mouse embryonic stem cells (mESC) into endothelial-like cells S. K. Jahn, T. Hennicke, G. Fritz (Düsseldorf)

p237 Propiconazole activates AhR in vitro and induces mixture effects with an established AhR ligand C. Knebel, a. braeuning, J. Neeb, A. Lampen, S. Hessel-Pras P. Marx-Stoelting (Berlin), O. Poetz (Tübingen), U. M. Zanger (Stuttgart)

p238 A combination of in-vitro and ex-vivo test models as an upstream alternative to regulatory OECD 403 animal studies D. Walter, D. Ritter, J. Knebel, K. Schwarz, T. Hansen (Hannover)

p239 In vitro and in vivo comparison of the skin sensitizing potential of UVCB substances used in cosmetic products M. Kleber (Düsseldorf), M. Flach, S. Kolle (Ludwigshafen a. R.) A. Mehling (Düsseldorf), S. Bade (Ludwigshafen a. R.) N. Watzek (Düsseldorf)

p240 Comparison of in vitro and in vivo testing methods for skin sensitization potential of polymeric substances M. Flach (Ludwigshafen a. R.), M. Kleber (Düsseldorf), S. Kolle L. Hareng (Ludwigshafen a. R.), A. Mehling, N. Watzek (Düsseldorf) S. Bade (Ludwigshafen a. R.)

p241 Porcine nasal mucosa as a suitable model for intranasal drug delivery S. Ladel, J. Flamm, S. Rosmer, J.-C. Walter, D. Filtzwieser, P. Schlossbauer P. Deing, K. Schindowski (Biberach a. d. R.)

8585


p242 Toxicity in A549 cells – a head to head comparison of air liquid interface and submerged exposure K. Gohlsch, T. Gudermann, H. Mückter, A. Breit (Munich)

p243 CAR-mediated expression of CYP2B1 in primary rat hepatocytes: A comparison between two isolation methods M. Wollenweber, D. Dimitrijevic (Kaiserslautern) B. van Ravenzwaay (Ludwigshafen a. R.), D. Schrenk (Kaiserslautern)

p244 Using the 3D hemicornea model for eye irritation benchmark testing of surfactants R. Balhorn, A. Fischer, K. R. Mewes, J. Feesche (Düsseldorf)

p245 Limited applicability of in vitro skin corrosion and irritation tests for agrochemical formulations S. Kolle, M. Remmele, B. van Ravenzwaay R. Landsiedel (Ludwigshafen a. R.)

p246 Establishment of a novel scaffold for the 3D cultivation of human hepatocytes M. Ruoß, C. Grom-Baumgarten, M. Weimer, A. Salzer, A. Nüssler (Tübingen)

p247 Is there hope to correctly classify severe ocular irritant agrochemical formulations using in vitro methods – a proof of concept using the Isolated Chicken Eye Test, two modified BCOP protocols and an EpiOcular™ ET50 protocol S. Kolle, M. Remmele, B. van Ravenzwaay R. Landsiedel (Ludwigshafen a. R.)

p248 Kinase safety – improving understanding and prediction of kinase safety liabilities in drug discovery R. Ziegler, C. McGinnis, L. Polonchuk, S. Kirchner (Basel/CH)

p249 BH3I-1 a BH3 mimetic induces and modulates stress-response D. Stucki, W. Stahl, P. Brenneisen (Düsseldorf)

p250 Limitations of in vitro/in chemico/in silico methods for skin sensitisation testing of 16 chemicals in the REACH context K. Tegethoff, D. Beyer, M. Schaub, H. Schlecker (Wuppertal) H. Bluhm (Leverkusen)

8686


p251 Establishment of a coculture of HaCaT keratinocytes and MUTZ-3 derived Langerhans cells for in vitro assessment of the skin sensitization potential of xenobiotics A. Sonnenburg, R. Kreutz, M. Peiser (Berlin)

p252 Comparative cytotoxicity of plant protection products and their active substances S. Adler-Flindt, S. Martin (Berlin)

p253 Impact of the circadian rhythm on the establishment of sensitive in vitro test systems J. Ndikung, M. Oelgeschlaeger, N. Ertych, D. Storm (Berlin)

p254 Cocultured activation test (COCAT) – advanced safety assessment of chemical sensitizers J. Hennen, J. Lichter, M. T. Schellenberger, N. Peter (Trier) S. Frey (Liebefeld/CH), S. Hoffmann (Paderborn), C. Eskes (Magliaso/CH) B. Blömeke (Trier)

p255 Hepatotoxic fungicides affect molecular targets associated with the AOPs for cholestasis and steatosis in vitro E. Zahn, C. Knebel, I. Aragao, S. Rieke, A. Braeuning, P. Marx-Stoelting (Berlin)

p256 Evaluation of nuclear receptor coregulator binding assay for testing of retinoic acid receptor alpha (RARα) active substances using a mechanistic- based approach P. Demuth, B. Birk, N. Roth, K. Sessler, H.-A. Huener, A. Verlohner, B. Flick B. van Ravenzwaay, R. Landsiedel (Ludwigshafen a. R.)

p257 Cellular redox regulation in resin monomer-exposed cells – role of glutathione H. Schweikl, C. Bolay, K.-A. Hiller, B. Graf, W. Buchalla M. Gruber (Regensburg)

p258 Levels of selected carcinogens in the emissions of “Heat not Burn” tobacco products N. Mallock, L. Böss (Berlin), R. Burk, M. Danziger, T. Welsch, H. Hahn H. L. Trieu, J. Hahn (Sigmaringen), E. Pieper, F. Henkler-Stephani, C. Hutzler A. Luch (Berlin)

8787


Toxicology – Biomonitoring/biomarkers in toxicology

p259 A mass spectrometric platform for the quantitation of mustard-induced nucleic acid damage T. Zubel, S. Kurzeja (Konstanz), A. Schmidt, D. Steinritz, H. John H. Thiermann (Munich), A. Bürkle, A. Mangerich (Konstanz)

p260 Untargeted identification and in vitro formation kinetics of pyrrolizidine alkaloid-derived protein adducts U. M. Herfurth, B. Monien (Berlin), A. Frolov (Halle a. d. S.), K. Abraham A. Lampen (Berlin)

p261 Recent advances in biomonitoring of human exposure to the mycotoxin citrinin G. Degen, N. Ali, U. Gundert-Remy (Dortmund)

p262 Comparison of isolation methods for detection of exosomal microRNAs in small urine volumes B. Petzuch, H. Ellinger-Ziegelbauer (Wuppertal)

p263 Impact of proliferating and differentiated keratinocytes on dendritic cell activation by contact allergens M. Silva e Sousa, J. Lichter, J. Hennen (Trier), F. Sahli E. Giménez-Arnau (Strasbourg/FR), B. Blömeke (Trier)

p264 Paraben concentrations in urine of preschool children – results of the 2nd human biomonitoring study in North Rhine-Westphalia, Germany L. Cladder-Micus, S. Rudzok, S. Sievering, M. Kraft, Y. Chovolou (Essen)

p265 A Geo-specific risk analysis of the coastal ecosystem – Increasing concern of carcinogenic and noncarcinogenic threat in humans, Bay of Bengal, Paradip, India S. Satapathy (Bhubaneswar/IN)

p266 Biomonitoring of 2,4,6-trinitrotoluene and degradation products in the marine environment with transplanted blue mussels (M. edulis) J. S. Strehse, D. Appel, C. Geist, H.-J. Martin, E. Maser (Kiel)

8888


Toxicology – Food toxicology

p267 Metabolism of cyclo-di (bisphenol-A-monoglycidylether) by human hepatic phase I enzymes S. Zellmer, K. Franziska, T. Bruhn, J. Weyer, I. Schirrmann, O. Kappenstein K. Pfaff, A. Luch (Berlin)

p268 Metabolism and mutagenicity of cis- and trans-anethole J. A. Fuhlbrueck, E. C. Schwind, A. Lencioni, M. J. Carlsson A. Cartus (Kaiserslautern)

p269 Toxicological risk assessment of pyrrolizidine alkaloids – investigations of hepatotoxic and mutagenic potential L. Rutz, L. Gao, K.-H. Merz, D. Schrenk (Kaiserslautern)

p270 Development of an analytical method for the simultaneous detection of veterinary drugs in agaricus bisporus c. neuber, M. Gehling (Berlin)

p271 Combinatory cytotoxic effects of asarone isomers in vitro T. Uebel, M. Wilken, H. Vu Chi, M. Esselen (Münster)

p272 The food contaminant 3-chloro-1,2-propanediol (3-MCPD) induces oxidative stress in mouse kidneys, testes and brain K. Schultrich, T. Buhrke (Berlin), C. Henderson, R. Wolf (Dundee/GB) A. Braeuning, A. Lampen (Berlin)

p273 Mutagenic potential of the α, β, γ, δ-unsaturated lactone protoanemonin M. Macziol, J. Eckerlein, A. Mainka, T. Sommer, G. Huang, M. Decker L. Lehmann (Würzburg)

8989

INDEX OF PRESENTING AUTHORS AND CHAIRS

aAbdel-Kahaar, E. 82Adler-Flindt, S. 86Ahrens, A. 24Aigner, A. 77Alfar, E. A. 76Algharably, E. 82Artusson, P. 55Atkinson, R. 65Au, B. 58Aulmann, W. 24Avramopoulos, P. 28

bBäckman, P. 53Backs, J. 33Bader, B. 44Bahar, M. A. 66Balhorn, R. 85Bamberg, E. 39Bankoglu, E. E. 42, 48Barg, M. 75Barth, H. 52Bauer, M. 54Bausch, A. E. 80Beer, L.-A. 71Behr, A.-C. 70Behr, C. 67, 70Behrends, S. 36Bekka, E. 68Benda, N. 45Bendiks, L. 40Bennien, J. 50Bermudez, M. 29Bert, B. 83Bertero, E. 52Bestehorn, K. 26, 31, 32, 51Betz, I. R. 59Beyer, N. 82Birk, B. 67Blömeke, B. 87Bock, A. 79Bode, G. 60, 63, 64Bode-Böger, S. M. 82Boobis, A. 41

Borchardt, H. 36Borghardt, J. M. 53Bosserhoff, A. K. 53Braeuning, A. 39, 84Breit, A. 56Breithaupt-Grögler, K. 46Brink, T. 61Brockmöller, J. 26, 30, 32, 43Broekmans, K. 79Bruhn, O. 50Bruns, T. 58Büch, T. 73Buesen, R. 30Bünemann, M. 29

cCaris, J. 83Carle, S. 71Cartus, A. 27, 41Cascorbi, I. 26, 38, 44Cestari, R. 83Chovolou, Y. 87Christmann, M. 36, 48, 73Clement, B. 43Cunha Fontele, S. B. 70Czich, A. 24

DDasgupta, P. 78Degen, G. 87Demuth, P. 86Derakhchan, K. 25Despang, P. 80Deutsch, B. 63Dienemann, C. 76Dieter, R. 80Disselhorst, J. 45Distler, J. 44Dobrev, D. 40, 52Donath, F. 47Dörner, M. 58Drexler, H. 52Dubrall, D. 51Dücker, C. 38, 59

9090


Dülk, R. 41Duque Escobar, J. E. 56Dworatzek, E. 44, 58

eEckhardt, I. 75El-Armouche, A. 33, 59Elgert, C. 60Engelhardt, S. 42, 44, 76Engeli, S. 29, 82Ernst, K. 35, 71Eschenhagen, T. 42, 78Escher, S. 31Esser, C. 68

fFabian, E. 66Felix, I. 71Fender, A. 49Fischer, A. 33Fischer, S. 35Flach, M. 84Frick, J. 42Friedrich, C. 46Friedrich, F. 37, 74Frings, S. 32Fritz, A. 63Fritzwanker, S. 57Fröba, J. 74Fröhling, S. 44Fuhlbrueck, J. A. 88Fuhr, U. 65, 73Funk, F. 76Fux, D. 36

GGaressus, E. D. G. 82Gaschler-Markefski, B. 32Gather, F. 49Gebel, T. 52Genth, H. 72Gerhard, R. 35Gessner, A. 63Geu, S. 34

Gibhardt, C. 52Giehl, K. 53Gierschik, P. 36, 63Giesen, J. 29Gilsbach, R. 28, 75Glaser, D. 59Glück, J. 83Goebel, C. 68Göen, T. 52Gohlsch, K. 85Golka, K. 48Gomes, C. 66Gömpel, K. 48Goody, D. 76Goss, K.-U. 38, 66Grabowski, M. 62Grandoch, M. 59Greim, H. 41Gresch, A. 80Griesbacher, T. 72Griesinger, C. 54Grimm, K. 56Groh, I. A. M. 61Groß, G. 43Grube, M. 81Grune, J. 37Gudermann, T. 40Gundert-Remy, U. 33, 41Guye, P. 44

HHaag, M. 56Haefeli, W. E. 34Hafner, S. 36Hagemann, A. 77Hamlin, R. L. 25Hammer, H. S. 27, 67Hanna, D. M. F. 60Hansen, A. 44Hartmann, C. 67Hartmann, G. 30, 67Haslacher, H. 54Hass, R. 53Hedtrich, S. 30, 64, 65

9191


Hein, L. 58Heintz, E. 34Heneka, M. 33Hengstler, J. G. 31Hennen, J. 86Henning, M. 41Henninger, C. 27, 37Herbert, J. 72Herfurth, U. M. 87Hertzsch, R. 83Heßmann, E. 53Hessel-Pras, S. 66, 67, 68Hintzsche, H. 39, 48Hinz, B. 36Hock, F. J. 25,58, 74Hoffmeister, T. 56Hofmanninger, J. 54Hölzer, D. 48, 73Holzer, P. 42Honnen, S. 27, 48Hsin, C.-h. 66Hundt, F. 41

IIlyaskina, O. 29Iyer, L. M. 28

JJaeger, S. 82Jäger, D. 32Jahn, A. 65Jahn, S. K. 84Jamra, S. 59Jansen, S. 75Jaron, M. 58Jarzina, S. 39Jedlitschky, G. 81Jelinek, V. 78Jensen, O. 38Juhasz, K. 64Juling, S. 70Jurida, L. 76Just, K. S. 38, 81

KKadhum, T. 69Kähler, M. 28Kaltenhäuser, J. 35Kalwa, H. 64Kämmerer, S. 80Kammerloher, W. 39Kauk, M. 57Keiser, M. 50Kemski, S. 30Kennel, L. 79Khobta, A. 27Kintscher, U. 37Kirchhofer, S. 78Kitsera, N. 69Kitzinger, R. 69Kleber, M. 84Kleinert, H. 60Klenk, C. 42, 79Kliewer, A. 78Klümper, T. 73Klußmann, E. 25Kockskämper, J. 52Kohl, Y. 70Kolahian, S. 49Kolle, S. 85König, J. 26, 50Köpp, F. 58Körbelin, J. 60Kortholt, A. 54Köster, K. 56Kracht, M. 62Kramann, R. 44Krasel, C. 79Krause, S. 66Kroemer, H. 30, 33Krüger, A. 72Krüger, M. 71Kucheryavenko, O. 68Kugler, N. 62Kühne, A. 81Küpfer, L. 26Kuret, A. 76Kurz, M. 78

9292


lLaarmann, K. 75Ladel, S. 84Landsiedel, R. 69Lang, D. 43Lange, V. 35Leao Santos, G. 77Lehnart, S. 54Leiss, V. 79Leist, M. 30Lemoine, L. 39Levent, E. 65Liaw, N. 59Lier, J. 63Lilienblum, W. 25Locci de Oliveira, M. 83Lomada, S. K. 77Lorenz, K. 33, 74Lu, R. 40Lukowski, R. 56Lutz, S. 44, 54

MMack, M. 69Mackensen, A. 43Macziol, M. 88Maimari, T. 57Majer, M. 79Malinowska, B. 74Mallock, N. 86Mally, A. 27, 35Malm, J. 52Mammes, F. 56Mangerich, A. 27, 48, 87Marquart, K. 67Martin, T. 35Martono, D. 38Marx-Stoelting, P. 86Maser, E. 43, 66Matt, L. 40Matthaei, J. 82Matthes, J. 72, 75Matthiesen, S. 30Mayr-Buro, C. 62Mederos y Schnitzler, M. 57Meier-Sölch, J. 49

Melching-Kollmuss, S. 35Mettke, K. 41Metzner, K. 33Meurer, M. 76Meyer, M. J. 81Meyer, T. 49Meyer zu Schwabedissen, H. E. 50, 55, 81Meyer-Roxlau, S. 59Michaelsen, S. 69Miess, E. 78Mikus, S. 41Mittag, A. 70Moepps, B. 29, 57, 61Moik, T. 63Monastyrski, D. 83Monien, B. 48Montag, G. 27Morhenn, K. 77Moritz, E. 29, 51Mösslein, N. 78Muehlich, S. 73Müller, S. F. 63

nNdikung, J. 86Neitzel, C. 73Neuber, C. 88Neumann, D. 49, 53Nickel, L. 75Nies, A. T. 50, 63Nikolaev, V. 57Nitsch, R. 33Noack, C. 25Nothjunge, S. 28Nührenberg, T. G. 75Nurulain, S. 29

oOdum, J. 33Oertel, R. 83Ost, S. 72Ostermeyer, J. 78Oswald, S. 38, 63, 81Ottmann, C. 54

9393


pPannirselvam, M. 25Papatheodorou, P. 35Peiser, M. 83Penning, T. 43Perl, S. 60Petrikat, T. 77Petz, A. 62Petzuch, B. 87Philippu, A. 53Plassmann, S. 46Plötz, T. 57Pointon, A. 25Popp, T. 71Pöppelmann, T. 64Przykopanski, A. 68

RRaad, F. 59Raasch, W. 56Rathjens, F. S. 37Rauch, B. H. 29Ravens, U. 42Rawish, E. 56Reichert, C. 77Reiners, O. 36Rekersbrink, T. 65Rengelshausen, J. 46, 47Reustle, A. 28Richling, E. 48Ritz, V. 24, 33Rolfes, K. M. 39Rothmiller, S. 27Ruoß, M. 85Rutz, L. 88

sSachse, C. 29Salako, O. 60Satapathy, S. 87Schäfer, A. 50Schäfer, B. 64Schanbacher, C. 37Schecker, N. 71Scheffler, H. 24

Schellenberger, M. T. 69Schindowski, K. 60Schirmer, B. 29Schlick, S. F. 76Schmeinck, S. 83Schmidl, D. 54Schmidt, G. 53Schmidt, M. 44, 54Schmidt, W. M. 54Schmiedl, S. 66Schmitt, A. 68Schmitz-Spanke, S. 52Schneckmann, R. 62Schneider, E. 61, 79Schneider, S. 35Schnell, L. 71Schober, L. 84Schöttelndreier, D. 71Schrenk, D. 41Schug, B. 46, 47, 53Schulte, J. S. 75Schulte-Hubbert, R. 48Schultrich, K. 88Schulz, M.-C. 39Schüngel, L. 51Schupp, N. 27Schwab, M. 30, 44Schwan, C. 61Schwaninger, M. 40Schwartz, M. 74Schweikl, H. 86Schwotzer, D. 70Sebens, S. 53Sehner, C. 24Seidl, M. D. 74Seifert, R. 64Seiwert, N. 69Sekeres, K. 65Sessa, M. 51Shahriyari, M. 30Sigaroudi, A. 51Sofranko, A. 68Solecki, R. 33Solemanizadeh, A. 64

9494


Sömmer, A. 37, 61Sonnenburg, A. 86Spickhoff, A. 34Stegmüller, S. 48, 72Steinborn, R. 57Stelmach, P. 82Stenzig, J. 74Stern, D. 35Sternberg, A. 59Stölzle-Feix, S. 80Storch, U. 57Stratz, C. 75Strehse, J. S. 77, 87Stucki, D. 85Sudhop, T. 32Sundaram M, S. 60

TTabari, D. 40Tarazona, J. 33Tegethoff, K. 85Thierbach, R. 70Throm, L. 61Tiburcy, M. 30, 44Timmer, W. 46Titz, B. 67Treue, S. 33Trueck, C. 51Tsoutsoulopoulos, A. 84Tsvilovskyy, V. 40Turner, R. 65Tzvetkov, M. V. 38, 50, 55, 63

UUebel, T. 88Unfried, K. 27

VVan de Voorde, J. 61van Hattum, H. 24van Heuveln, J. 37Vehreschild, M. 42Voigt, N. 29, 50, 52, 80vom Brocke, J. 35von Kügelgen, I. 60

WWagner, S. 65Walliser, C. 36Walter, D. 84Walther, U. 64Wannick, M. 65Waterkamp, D. 32Watz, H. 53Weber, A. 62Weber, T. 76Wegner, M.-S. 81Weinberger, F. 58Weindl, G. 49, 62Weiser, T. 65Weiterer, S.-S. 28Wensing, G. 46, 47, 51, 53Wenzel, J. 40Werner, M. 24Werntz, L. 66Wessler, I. 47

9595


Westphal, G. 84Wieland, T. 42, 52Wiesemann, C. 34Wilhelm, M. 72Willbold, D. 40Wist, M. 77Wolf, R. 50Wollenweber, M. 85Wolter, S. 79Wunder, F. 64

XXimenez, J. P. 81

ZZafeiriou, M.-P. 40Zahn, E. 86Zanger, U. M. 55Zayed, A. 29Zeisberg, E. 42, 44Zeisberg, M. 42, 44Zeiser, J. 39Zelarayán, L. C. 28Zellmer, S. 88Zeuzem, S. 32Zhang, J. 80Zhu, Z. 71Zhupanyn, P. 73Ziegler, R. 85Zimmermann, W.-H. 25, 30, 31, 39, 42, 44Zolk, O. 72Zubel, T. 87

9696

noTes

9797

noTes

9898

noTes

- Aktuelles aus der Forschung- Nachrichten- Cartoons- Erlebnisse einer TA- Stellenmarkt- Kurse/Kongresse/Vorträge- Kommentare- Arbeitsgruppen-Portraits- Rätsel- Bücher- Methoden/Tipps und Tricks- Produktübersichten- Publikations-Ranking

Spaß am Lesen?Kostenlos?Gibt’s nicht!

Gibt’s!Ins Labor schicken wir Ihnen Laborjournal kostenlos. Zehn mal im Jahr. Einfach bestellen: http://www.laborjournal.de/rubric/abo/sub1.lasso?mcompany=0&process=0

Eigenanzeige_DGPT_Kongressheft_2018_Print.indd 1 30.01.18 16:30

- Aktuelles aus der Forschung- Nachrichten- Cartoons- Erlebnisse einer TA- Stellenmarkt- Kurse/Kongresse/Vorträge- Kommentare- Arbeitsgruppen-Portraits- Rätsel- Bücher- Methoden/Tipps und Tricks- Produktübersichten- Publikations-Ranking

Spaß am Lesen?Kostenlos?Gibt’s nicht!

Gibt’s!Ins Labor schicken wir Ihnen Laborjournal kostenlos. Zehn mal im Jahr. Einfach bestellen: http://www.laborjournal.de/rubric/abo/sub1.lasso?mcompany=0&process=0

Eigenanzeige_DGPT_Kongressheft_2018_Print.indd 1 30.01.18 16:30

Analyte GroupWholeBlood

Serum Urine Hair Aqueous

Drugs of Abuse X X X X

Therapeutic Drugs X X X X

Replacement Drugs X X X X

Ethanol X

Alcohol Consumption Markers X X X

Benzodiazepines X X X

Neuroleptics X

Antiepileptics X

Blank ontrolsC X X X

YOUR PARTNER FOR QUALITY

Accuracy controls

Creating reliable solutions

Available Products & Matrices

ACQ Science has a proven track-record in developing leading- edgeanalytical reference material for toxicologic, forensic, and clinicalapplication with a comprehensive portfolio of controls and customizedsolutions for your laboratory's needs.

If you are looking for different parameters, we are happy to assist you withbuilt-to-order standards and controls.

Check our website for more information orwww.acq-science.decontact us at [email protected]

ACQ Science GmbHEtzwiesenstraße 3772108 Rottenburg-HailfingenGermanyPhone: +49 (0)7457 94693 0Fax: +49 (0)7457 94693 69Email: [email protected]: www.acq-science.de

Certified according toISO 9001:2008ISO 13485

PROGRAMME - Tox€¦ · Pharmacology (DGP/SPS/DZHK – Preclinical Drug Development) 40 EUR...

Documents

Transcript of PROGRAMME - Tox€¦ · Pharmacology (DGP/SPS/DZHK – Preclinical Drug Development) 40 EUR...